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RESUMO 
 
 A depressão é uma doença psiquiátrica multidimensional que afeta cerca de 350 milhões 
de pessoas em todo o mundo. O uso de modelos animais é muito importante no contexto da 
investigação e desenvolvimento de novos medicamentos para tratar a depressão, na fase de 
ensaios pré-clínicos. No entanto, a criação de modelos animais de depressão válidos e eficazes 
tem sido um desafio para vários investigadores deste campo.  
Os modelos mais usados são baseados nos seguintes critérios de validação: semelhança 
(face validity), homologia (construct validity) e predição (predictive validity), validados por 
Willner. O critério de semelhança diz respeito à capacidade do modelo de mimetizar os principais 
sintomas da doença. O critério de homologia tem em consideração a fundamentação teórica por 
detrás das características observadas e o critério de predição avalia a correlação com a eficácia 
do tratamento na clínica. 
Há vários modelos animais de depressão, uns são baseados na exposição ao stress, outros 
em manipulações (bio)químicas, outros baseados em genética e há mesmo alguns derivados de 
lesões. Para estudos pré-clínicos os modelos baseados na exposição ao stress são os mais 
fidedignos porque permitem uma avaliação do fármaco num organismo, enquanto sistema 
integrado. Para além disso, o stress crónico moderado e imprevisível (uCMS) é um modelo 
amplamente utilizado pela sua similaridade etiológica com a doença humana e pelo 
preenchimento de todos os critérios de validação referidos. A principal fraqueza do modelo é a 
sua pouca reprodutibilidade entre laboratórios, muito provavelmente derivada da falta de 
padronização. Adicionalmente, trata-se de um modelo moroso, exigente do ponto de vista 
operacional e suscetível a variabilidade na execução do protocolo. 
Para ultrapassar estes problemas, a empresa onde desenvolvi esta tese de mestrado, 
Bn’ML – Behavior and Molecular Lab, desenvolveu um equipamento capaz de executar o 
protocolo de uCMS de uma forma padronizada e automatizada. Esta empresa é uma start-up da 
Universidade do Minho que trabalha na avaliação de efeitos comportamentais e moleculares de 
compostos terapêuticos, em modelos animais de doenças psiquiátricas. 
Este trabalho, desenvolvido no laboratório ICVS/3B’s  - onde está incubada a Bn’ML, teve 
2 objetivos principais: o primeiro foi o acompanhamento e supervisão da construção do protótipo 
assim como o teste e melhoramento individual dos stressores adaptados; o segundo foi a 
validação do protocolo de uCMS adaptado num estudo piloto utilizando um pequeno número de 
animais. 
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No âmbito do primeiro objetivo concluímos a construção do protótipo (semelhante a 
uma rack) e conectámos este equipamento a um computador, o que permitiu a robotização de 
um processo que era integralmente executado pelo operador. De seguida reformulámos alguns 
dos stressores que fazem parte do protocolo de uCMS, para isso dividimo-los em três categorias 
principais: stressores totalmente automáticos, stressores parcialmente automáticos  e stressores 
não automáticos. Os stressores totalmente automáticos foram introduzidos nas funções do 
equipamento - estes stressores são executados sem qualquer manipulação por parte do 
operador. Stressores parcialmente automáticos não são controlados pela rack mas a sua forma 
de implementação foi modificada de forma a ser adaptada a uma estrutura de mais fácil uso para 
o operador. Finalmente, stressores não automáticos refere-se aos que permaneceram iguais e 
portanto a sua execução foi exatamente igual à do protocolo original. Após provar que estes 
stressores adaptados desenvolviam a uma resposta ao stress similar aquela que ocorre em 
stressores originais (através do seu teste individual com animais), estes stressores foram 
integrados no equipamento para possibilitar o desenvolvimento de um protocolo completo, no 
formato de um estudo piloto. 
Para o segundo objetivo, integrámos todas as adaptações ao protocolo original (uCMS) 
num estudo piloto, o que nos possibilitou atingir resultados úteis e originais no que diz respeito 
às abordagens técnicas e metodológicas. Os principais resultados obtidos foram a redução do 
espaço necessário para executar este protocolo, a poupança de tempo, a diminuição da 
intensidade de trabalho, uma exposição mais uniforme das caixas dos animais ao protocolo 
(menos variabilidade), assim como a redução da manipulação dos animais. Estas alterações 
podem contribuir para ultrapassar as conhecidas limitações do protocolo de uCMS.  
Os resultados do estudo piloto foram avaliados para perceber se os critérios de validação 
propostos foram preenchidos. Para isso, um grupo de animais foi exposto ao protocolo 
automatizado (auCMS) e comparado com o grupo exposto ao protocolo manual (uCMS) e com o 
grupo controlo (CT). Alguns animais do grupo de auCMS foram tratados com um antidepressivo, 
a fluoxetina, para verificar a sua capacidade de reverter o fenótipo induzido. Os critérios de 
validação foram avaliados através de análises moleculares e celulares (critério de homologia), 
testes comportamentais (critério de semelhança) e eficácia do tratamento (critério de predição).  
A nível molecular, os níveis de corticosterona mostraram uma disrupção do padrão de 
secreção desta molécula nos animais expostos ao auCMS, tal como foi observado com o grupo 
uCMS. Relativamente à morfologia dos neurónios do giro dentado do hipocampo, ambos os 
grupos stressados (uCMS and auCMS) apresentaram resultados inconclusivos no que diz respeito 
ao comprimento das dendrites e à complexidade dos neurónios do giro denteado dorsal. Apesar 
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da validação da componente molecular, o critério de homologia foi apenas parcialmente validado 
devido à falta de dados robustos na componente celular.  
O critério de semelhança (face validity) foi avaliado através de testes comportamentais 
para as 3 dimensões (cognição, ansiedade e humor), conhecidas por estar afetadas nesta doença. 
Resultados da cognição e ansiedade apresentaram diferenças significativas entre o grupo 
controlo e o grupo auCMS, com pior desempenho deste último grupo. A dimensão do humor foi 
avaliada através de 3 testes diferentes: SPT e SDT (testes anedónicos) que apenas mostraram 
diferenças significativas entre o grupo CT e o grupo uCMS; e pelo FST (teste de desamparo 
aprendido) que mostrou diferenças significativas entre o grupo controlo e o grupo auCMS. Estes 
resultados, pouco claros, podem estar relacionados com as dificuldades metodológicas deste tipo 
de testes. Apesar destas inconsistências, é possível alegar uma validade deste critério, visto que 
todos os testes comportamentais apresentaram piores desempenhos do grupo auCMS quando 
comparado com o grupo CT, sendo que naqueles onde não há estatística significativa existe uma 
tendência nesse sentido. 
Por último, uma parte dos animais do grupo auCMS foram tratados com fluoxetina e 
expostos aos mesmos testes comportamentais. Apesar de nem todos atingirem a validade 
estatística, os resultados mostram uma melhoria do grupo tratado em todos os testes, o que 
poderá ser considerado como um preenchimento do critério de predição.  
Para além destes critérios, Belzung introduziu outro conceito que pretende validar as 
estirpes usadas. O nosso estudo também teve em conta este parâmetro, uma vez que a nossa 
escolha recaiu nos Wistar Han – uma estirpe consensualmente aceite para estudar a depressão. 
No geral, tendo em conta os critérios de validação analisados os resultados revelaram-se 
promissores visto que a maioria dos resultados do protocolo automatizado revelaram uma 
resposta similar ao manual e divergente dos controlos.  
É importante não esquecer que este estudo piloto produziu resultados preliminares 
baseados num pequeno número de animais, o que levanta a necessidade de repetir a experiência 
para confirmar os resultados observados. Outra limitação está relacionada com a natureza em si 
de um estudo piloto, como foi o primeiro estudo desenvolvido com o equipamento algumas 
necessidades de aperfeiçoamento foram identificadas. Tal como esperado, ocorreram algumas 
falhas do equipamento assim como erros no protocolo programado; estas questões foram 
prontamente resolvidas mas ainda assim estes problemas podem ter influenciado a indução de 
stress nos animais e pode ter sido a causa para algumas alterações na aquisição do fenótipo.  
Apesar de este trabalho ter sido desenvolvido para estudar a depressão através de um 
protocolo de exposição a stress crónico, o equipamento apresentado pode ser usado para outras 
doenças uma vez que este é capaz de desenvolver outro tipo de protocolos. 
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Nós acreditamos que esta inovação permitirá obter modelos animais mais robustos e 
fidedignos. De facto, modelos animais viáveis são cruciais para a investigação em ciências da 
saúde, particularmente para a melhoria das abordagens pré-clínicas atuais. Considero assim, que 
se deu um passo importante para o progresso no campo da investigação pré-clínica. 
 
PALAVRAS-CHAVE: depressão, modelo animal, validação, stress  
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ABSTRACT 
 
Depression is a multidimensional psychiatric disorder that affects around 350 million 
people worldwide. In order to study new treatment approaches for this disease it is of major 
importance to use animal models. However, the generation of valid and effective animal models 
of depression has been a challenging task for many researchers that work in this field.   
The mostly used models are based on the following validation criteria: face, construct 
and predictive, validated by Willner. Face validity is whether the model mimics the core 
symptoms of the disease, construct validity takes into account the theoretical rational behind the 
features observed and predictive validity evaluates its correlation with treatment efficiency in the 
clinics. 
There are several animal models of depression, some are based on stress exposure, 
others on (bio)chemical manipulations, others are models based on genetics or even derived from 
lesions. For pre-clinical studies the models based on stress exposure are the most reliable because 
they allow to evaluate the effects of a drug on an organism, as an integrated system. Furthermore, 
the Unpredictable chronic mild stress (uCMS) is a widely used model, based on stress, mainly due 
to its etiological similarity with the human disease and also for the fulfilment of all the validation 
criteria mentioned before. The main weakness of this model is its reduced reproducibility 
between laboratories, most likely to derive from the lack of standardization. Additionally, this 
model is very time-consuming, demanding from the operational point of view and susceptible to 
variability in protocol execution.  
In order to overcome these issues, the company where I performed this master thesis, 
Bn’ML – Behavior and Molecular Lab, developed an equipment capable of performing the uCMS 
protocol in a standardized and automated manner. This company is a start-up from the University 
of Minho that works in the evaluation of behavioural and molecular effects of therapeutic 
compounds, in animal models of psychiatric diseases. 
This work was developed at the ICVS/3B’s laboratory, where B’nML is incubated and had 
two main goals: the first was the accompaniment and supervision of the prototype construction 
as well as to test and improve the adapted stressors, individually ; the second was to validate this 
protocol adaptation in a pilot study with a small cohort of animals.  
Within the scope of the first objective, we completed the prototype construction (similar 
to a rack) and connected this equipment to a computer, which allowed the robotization of a 
process that was fully executed by the experimenter. Then, we reformulated some of the actual 
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stressors that are part of the uCMS protocol, for that we divided them into three main categories: 
total automated stressors, partial automated stressors and non-automated ones. 
 Total automated stressors were introduced in the equipment functions – these stressors 
are performed without any manipulation of the experimenter. Partial stressors are not controlled 
by the rack but their way of being implemented was modified in order to adapt to a more user-
friendly structure. Finally, non-automated stressors refers to the ones that remained unchanged 
and so their execution was exactly the same as in the original protocol. After proving that these 
adapted stressors could lead to a similar stress response when compared to the original stressors 
(through their individual test with animals), these adapted ones were integrated into the 
equipment to allow the performance of a complete protocol, in a pilot study format.   
For the second objective, we integrate all the adaptations to the original procotol (uCMS) 
in a pilot-study, which enable us to reach useful and original outcomes with regard to technical 
and methodological approaches. The main outcomes obtained were a space-demanding 
reduction, saving time, a decrease in labour-intensity work, a more uniform exposure of the cages 
to the protocol (less variability) as well as a reduction of experimenter manipulation of the 
animals. These alterations may contribute to overcome some known limitations of the uCMS 
protocol. 
The results from the pilot study were evaluated to understand if the proposed validation 
criteria were fulfilled. For that, a group of animals was exposed to the automated protocol 
(auCMS) and compared to a group exposed to the manual protocol (uCMS) and to the control 
group (CT). Some of the animals from the auCMS group were treated with an antidepressant, 
fluoxetine, to verify its ability to revert the induced phenotype. The validation criteria were 
assessed through molecular and cellular insights (construct validity), behavioural tests (face 
validity) and treatment efficacy (predictive validity). Molecular findings from corticosterone levels 
showed a disruption of the circadian regulation of animals exposed to auCMS, like it was observed 
with the uCMS group. Regarding neuronal morphology in the hippocampal dentate gyrus (DG), 
both stressed groups (uCMS and auCMS) showed unclear results in dendritic length and in 
complexity of dorsal DG neurons. Despite the validation of the molecular component, construct 
validity can only be partially validated due to the lack of robust results from cellular findings. 
Face validity was evaluated through behavioural tests for the 3 dimensions (cognition, 
anxiety and humor), known to be affected in this disease. Results from cognition and anxiety show 
significant differences between control group and auCMS group, with a worse performance of 
this last group. Mood dimension was assessed through 3 different tests: SPT and SDT (anehonic 
tests), in which we only observed statistical differences between the CT and uCMS groups; and 
xvii 
 
the FST (learn-helplessness test) that showed statistical differences between the CT and auCMS 
groups. These unclear results can be related to methodological difficulties of this type of tests.  
Despite this inconsistence it is possible to claim a validation of this criteria since all the 
behavioural tests showed a worse performance in the auCMS group when compared to CT ones, 
and in those where there is not a statistical significance it exists a tendency in that way.  
  Lastly, some animals from the auCMS group were treated with fluoxetine and allowed to 
perform the same behavioural tests. Although not all animals reached statistical differences, 
results showed an improvement of the treated group in all the tests, which may be considered a 
fulfilment of the predictive validity. 
Apart from these criteria, Belzung introduced another concept that intends to validate the strains 
used. Our study also took this parameter into account since our choice relapsed on Wistar Han – 
a strain that is consensually accepted to study depression.  
Overall the validation criteria evaluated showed promising results since the majority of 
them indicate a similar response to the manual protocol and divergent from the control ones.  
Importantly, this pilot study produced preliminary results based on a small number of 
animals raising the need to repeat the experiments in order to confirm the results observed. 
Another limitation is related to the nature of a pilot study itself, as it was the first study developed 
with the equipment and some improvement needs were identified. As it was expected, some 
failures of the equipment occurred as well as errors in the programmed protocol; these issues 
were promptly resolved, however, these problems may have influenced the animals stress 
induction and could have been a cause for some alterations in the phenotype acquisition. 
Although this work has been developed to study depression through a protocol of chronic 
stress exposure, the stated equipment can be used for other diseases since it is capable of 
performing other types of protocols. We believe that this innovation will allow developing more 
robust and reliable animal models. In fact, viable animal models are crucial to health sciences 
research, particularly to the improvement of the actual pre-clinical approaches. I consider that an 
important step toward progress in the field of preclinical research has been made.  
  
KEY-WORDS: depression, animal model, validation, stress   
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1. INTRODUCTION 
 
1.1 Depression 
 
1.1.1 Global impact 
Major depressive disorder (MDD) is a highly prevalent mood disorder, known to affect 
around 350 million people worldwide(1). According to the World Health Organization, MDD will 
be the second leading cause of disability worldwide by 2020. This disorder affects more women 
than men and it often appears at a young age(2,3). Moreover, this disease affects various 
functioning areas like social, professional or occupational, posing a tremendous burden on 
society. 
 
1.1.2 Diagnosis 
According to Diagnostic and Statistical Manual of Mental Disorders (DSM)-V, MDD is 
defined by, at least, one major depressive episode (MDE) as well as the absence of mania and 
hypomania(4). Nine symptoms can be present in an MDD patient: loss of interest or pleasure in 
usually pleasurable situations or activities (anhedonia), depressed mood, change in appetite and 
weight, loss of energy, less concentration, changes in sleep patterns, guilty feelings or 
worthlessness, psychomotor retardation or agitation and suicidal ideation. To be considered a 
MDE, five of these nine symptoms must be present during the same 2-week period, being 
depressed mood or anhedonia one of them. During this 2-week period the required frequency 
can vary by symptom but most of the times it needs to be present almost every day (4). 
MDD can be considered a multi-dimensional psychiatric disorder because it often covers 
impairments in different behavioural domains, including cognition, anxiety and mood(5). Indeed, 
generalized anxiety disorder (GAD) seems to appear more nosologically related to MDD than 
previously thought due to high comorbidity between mood and anxiety disorders (6). Cognitive 
impairments have also been commonly associated with MDD, particularly executive 
dysfunction(7). 
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1.1.3 Treatment 
Antidepressants are the first line treatment for depression. Still, many patients do not 
benefit from currently available antidepressants. According to START*D (Sequenced Treatment 
Alternatives to Relieve Depression) trial, which was an interesting study that gathered data about 
the effectiveness of antidepressant drugs treatment in MDD patients, only 28-33% of the patients 
remitted after the first antidepressant treatment(8). This trial was the largest and longest study 
ever conducted to evaluate depression treatment(9). This rate of remission is quite low for a 
disease with such prevalence, reflecting the need for the development of new antidepressants.  
Antidepressants may be divided in several classes. First-line antidepressants to treat MDD 
are selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake 
inhibitors (SNRIs) because they are associated with a better safety profile and tolerability. SSRIs 
include fluoxetine, sertraline, paroxetine, fluvoxamine, citalopram and escitalopram whereas 
SNRIs encompass venlafaxine and duloxetine. 
Tricyclic antidepressants (TCAs) are other class of antidepressants which inhibit the 
reuptake of both serotonin and norepinephrine by blocking each transporter. However they are 
not specific and they also block other receptor sites (like histaminic, cholinergic, and α1 -
adrenergic). These are recommended as second-line antidepressants while monoamine oxidase 
inhibitors (MAOIs) are third-line antidepressants due to their increased number of side effects 
(10,11).  
In persistent and severe cases, where antidepressants fail or produce insufficient 
response, combination of antidepressants are a frequently used strategy or, even its 
augmentation by the use of other drug classes like antipsychotics.  
In particular cases, non-medication treatments are also chosen, including deep brain 
stimulation, electroconvulsive therapy and vagus nerve stimulation (12). 
 
1.1.4 Aetiology 
Depression is thought to result from the interplay between genetic and environmental 
factors(13,14). Genetic contributions are relevant to the onset of depression, however, 
heritability is only moderate (40% to 50%) and as such, depression is not simply considered a 
genetic disorder(15). Taking into account that around 60% of the factors involved in depression 
aetiology are not explained by genetic variability, environmental features were shown to play a 
crucial role in depression(16). 
Stress is a widely known environmental precipitating factor for this disease(17–19). 
However, not all stress types are maladaptive (20). Many factors are used to categorize stress; 
Chapter 1. Introduction 
3 
 
the effects of stress depend on the neurodevelopment stage (for example childhood adversity is 
a major risk factor for depression), the intensity and duration, the nature, the predictability and 
controllability (21). As such, stress within specific contexts or exceeding a certain intensity and/or 
duration can affect physiological and behavioural homeostasis, leading to maladaptive 
responses(22). Additionally, individual susceptibility, i.e. the way different individuals cope with 
stress is highly variable, depending on (epi)genetic elements. Understanding the mechanisms and 
the conditions for these variations is crucial to improve knowledge on the etiopathogenesis of 
neuropsychiatric disorders (21,23). 
Among all the stress types, chronic stress has a leading position within environmental 
precipitating factors contributing to the development of MDD. As I will explain next, 
hypothalamic-pituitary-adrenal axis (HPA-axis) deregulation is one of the links that I will approach 
to explain this relationship between stress and depression. 
 
1.1.5 Pathophysiology of Depression 
The Central Nervous System (CNS) is responsible for the processing of both external and 
internal inputs and for adjusting responses according to possible changes or stimuli. 
Neuroimaging and postmortem studies in depressed patients have revealed changes in several 
brain regions. Structural and functional alterations in the prefrontal cortex (PFC) and 
hippocampus can explain the cognitive alterations usually observed in patients, like memory 
impairments, hopelessness or suicidal ideation. Amygdala, as well as related parts of the striatum 
(mainly ventral tegmental area and nucleus accumbens), are involved in the reward responses 
and in mediating aversive stimulus; these structures are known to be affected in depression since 
hedonic deficits, anxiety and decreased motivation is often seen in depressed patients(24). 
In summary, neural circuitry pathways involved in emotion, reward response and 
executive function are impaired in this disease(12). In depression, it is possible to observe the 
disruption of a wide variety of systems that will be next briefly described: 
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            Figure 1. The Hypothalamic-Pituitary-Adrenal axis in Depression (25) 
 
1.1.5.1 Neuroendocrine system 
The Hypothalamic-Pituitary-Adrenal (HPA) axis controls glucocorticoids (GCs) release, a 
system deeply involved in stress response and in depression.  
Stress is perceived in the cortex and this sensory information is transmitted to the 
hypothalamus where corticotropin-releasing factor (CRF) is released. This results in the secretion 
of the corticotropic hormone (CRH) from the anterior pituitary which will, in turn, stimulate the 
release of GCs from the adrenal cortex (cortisol in humans and corticosterone in rodents)(12). In 
fact, around 50% of depressed patients show elevated cortisol levels in the plasma and CRH in 
the cerebrospinal fluid(25). These GCs will activate the HPA axis through the binding to high-
affinity MR (mineralocorticoid) and low-affinity glucocorticoid receptors (GR) – highly expressed 
in the hippocampus. The physiological regulation of this axis occurs by negative feedback 
triggered when GCs bind to their receptors. 
In depressed patients, there is an hyperactivity of the HPA axis manifested by the increase 
of CRF and reduced feedback inhibition of the axis(12). This loss of the negative feedback loop is 
explained by a decrease of corticosteroid receptors in the hippocampus and PFC, also responsible 
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for the negative regulation of the HPA axis. As a consequence, this will lead to a persistent 
elevation of GCs secretion(22) (Fig 1). 
Importantly, genetic studies also found a correlation between the genes encoding 
proteins involved in the regulation of the HPA axis and some variables related to the severity of 
the disease and its response to antidepressants(26). 
 
1.1.5.2 Neuroimmune system 
The neuroimmune system is associated with neuroinflammation and the neuroendocrine 
system, known to be affected in depression(27). Indeed, patients of infectious and autoimmune 
diseases often show depressive symptoms that are reverted with antidepressants(25). The other 
way around seems also to be true as MD patients have increased levels of the proinflammatory 
cytokines, tumor necrosis factor-α and interleukin-6(28), which were shown to affect the HPA 
axis and monoamines expression(25). 
Similarly, chronic mild stress in rodents triggers the production of inflammatory cytokines 
with an increase of interleukin-1𝛽, tumor necrosis factor-α, interleukin-6 and interleukin-4 
expression(29). Cytokine changes may be secondary to the stress associated with the illness and 
may not be related to the mood disturbance per se. In fact, cytokine elevations are most 
predominant in severe depression(30). Some explanations are beginning to emerge, suggesting 
that this elevation in cytokine levels may contribute to some aspects of the atypical 
symptomatology, including decrease in sex drive, increased sleep and muscle fatigue, which are 
well documented effects of proinflammatory cytokines.  
 
1.1.5.3 Neurotransmission 
A decrease monoaminergic neurotransmission was proposed as a model to explain the 
pathophysiology of depression. This proposal was based on the knowledge that mono amine-
based agents are potent antidepressants – strong predictive validity(31). Indeed, norepinephrine 
and serotonin have critical roles in the mechanisms of action of several pharmacological 
treatments. However, serotonin and norepinephrine depletion does not induce depressive 
symptoms in healthy individuals(32).  
The cause of depression is far from being a simple lack of central monoamines. Some 
results suggest that pre-synaptic monoaminergic receptors (that modulate monoamine release) 
have a reduced sensitivity with depression. Also, second-messengers of the signalling cascade of 
serotonergic and noradrenergic systems were shown to have a reduced functioning, which may 
impair neurotransmitter activity even without changing monoamine levels or receptor numbers.  
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As a result, caution must be taken when associating depression with a direct reduction in 
monoamine neurotransmitters(25,31).  
Apart from monoamines, other neurotransmitters seem to be altered in depression, 
specifically glutamate which is the major excitatory neurotransmitter in the brain. A post-mortem 
study in brain tissue showed an increase in glutamate levels in the frontal cortex of MDD 
individuals and a decrease of plasma glutamate levels after antidepressants treatment(33). 
Contrary, other studies show increased levels of this neurotransmitter in the occipital cortex(25) 
and decreased levels in the prefrontal cortex of depressed patients(34), these inconsistent results 
need to be clarified in future studies. 
Additionally, some studies show reduce expression of excitatory aminoacid transporters 
(EAAT1 and EAAT2) as well as glutamine synthetase (convert glutamate to glutamine) within glia 
in several brain regions of MDD patients. In line with this, a role of glia was reported with 
impairments glutamate uptake and metabolism(22,33).  
Animal models support this findings, acute stress exposure induced an increase of 
extracellular glutamate in the hippocampus, amygdala and PFC. Repeated restraint stress lead to 
a reduction in AMPA-R and NMDA-R mediated synaptic currents in the PFC(22,33). Although, 
most of the animal findings support the idea that GC induces the enhancement of excitatory 
transmission there are some gaps between stress paradigms outcomes and their relationship 
with this NT that must be clarified (33).  
Supporting the importance of this NT in depression, ketamine has appear as a putative 
innovative antidepressant.  Actually, drugs that target the glutamate system must be deeply 
studied because they could bypass the typical delay of action of monoaminergic drugs (33). 
Ketamine, one of the most common NMDA antagonists, this drug is also an activator of AMPA 
receptors and an agonist of the D2 receptor of dopamine is an example of that(35). It was shown 
that a single subanesthetic dose of this drug was able to induce rapid and sustained 
antidepressant efficacy in depressed and treatment-resistant patients. In chronic stress rodent 
models, ketamine showed antidepressant-like properties, promoting an increase in synaptic 
connectivity and reversing the neuronal atrophy and behavioural deficits(36). Recent studies also 
suggest that antidepressant-like effects of NMDA antagonists depend on the enhancement of 
AMPA-R activation, which increases expression of BDNF and stimulates neurogenesis(33). 
Another neurotransmitter that has been under study in depression is GABA, the main 
inhibitory neurotransmitter of the brain. Alterations of the GABAergic system in depression are 
not well understood yet(36,37). Some studies in MD patients reported reduced levels of GABA in 
the plasma, occipital cortex, PFC and cerebrospinal fluid. Unmediated depressed individuals also 
showed decreased protein and mRNA levels.  This was also reported for PFC  as well as decreased 
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protein and mRNA levels of glutamic acid decarboxylase (GAD) 67 (a GABA synthesizing enzyme) 
(25,36,37), which was not evident in treated patients. Additionally, remission from depression of 
patients exposed to SSRIs or transcranial magnetic stimulation was shown to be linked with the 
normalization of GABA levels. 
Studies with animal models (GABAA mutant mice) showed that GABAA reduced receptor 
binding leads to an anhedonic phenotype. Several animal models of chronic stress report a 
decrease of expression of GABAA receptor in frontal cortex and other brain regions. Another 
approach to study this NT was through the administration of GABA directly in the hippocampus 
of rats which protected them from developing learned helplessness(37). 
Although some studies have been made in this topic further analysis need to be made in 
order to ensure robust outcomes. 
 
1.1.5.4 Neurotrophic factors  
Neurotrophic factors are key molecules for growth, survival and differentiation of neural 
cells; in particular neurotrophins are proteins that act in neurons (38)(39).  
Brain-derived neurotrophic factor (BDNF) is an important neurotrophin shown to be 
involved in depression pathophysiology. Clinical studies demonstrated that BDNF levels in the 
serum were decreased in drug-free MDD patients when compared to healthy participants; other 
studies reported increased BDNF levels after antidepressant treatment (more prominent in 
responders rather than non-responders). However, no clear relationship was shown between 
BDNF levels and depression severity(40). 
Animal models of stress also show a downregulation of BDNF in several hippocampal sub-
regions (dentate gyrus, CA3 and CA1), which has a negate impact in neuronal plasticity. Also, an 
experiment where exogenous corticosterone was administrated to rats showed that BDNF 
expression was reduced in hippocampus. According to that, a single infusion of BDNF into the 
hippocampus of animals produced a massive and long-lasting antidepressant effect(39). Actually, 
the majority of the current available antidepressants increase BDNF expression (in regions as 
hippocampus and prefrontal cortex of animals exposed to stress). Moreover, the efficacy of ADs 
is very reduced when BDNF expression or TrkB signalling are disrupted(41). 
Pre-clinical studies show that an impaired BDNF expression does not lead to depressive-
like behaviour but does affect ADs efficacy, apparently it seems that most of the BDNF role is 
involved with therapeutic action(41). 
Not in line with the beneficial effects of BDNF is the finding that inflammation in the brain 
and some neurotoxins increase brain BDNF levels. In the same way, blockade of BDNF activity in 
the Ventral Tegmental Area - Nucleus Accumbens (VTA-NAc) pathway exerts an antidepressant-
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like effect in rodent models of stress(42). Other findings show that chronic stress cause an 
upregulation of BDNF in the basolateral amygdala(43). 
It is clear that BDNF actions are not always beneficial, so a region-specific BDNF signalling 
is being studied as well as its impact through epigenetic modifications (e.g maternal separation 
early in life is capable of influencing this mechanism)(25,42). Epigenetic processes are very 
dynamic and tissue specific. Some groups have reported a hypermethylation of the BDNF gene 
promoter in MDD patients, a post-mortem analysis of patients that commit suicide have reported 
a lower BDNF expression, in Wernicke’s area, associated with an increase of DNA methylation of 
four CpG sites located at BDNF promotor 4. 
Studies are not limited to BDNF, for example nerve growth factor (NGF) has also been 
shown to be decreased in the hippocampus of suicide victims as well as in animals exposed to 
stress(44). Additionally, NT-3 was also reduced in the hippocampus after stress exposure(45). 
Moreover, an infusion of this neurotrophic factor in the hippocampus produced an 
antidepressant response in the forced swimming test (FST)(44). 
Another neurotrophic factor implicated in depression is the glial cell-line derived 
neurotrophic factor (GDNF). Some studies showed a decreased expression of this protein in the 
peripheral blood of depressed patients and reduced levels in the hippocampus were observed in 
a rodent model of chronic unpredictable stress(46). 
 
1.1.5.5.Neural plasticity 
Neural plasticity is a process that include re-organization of dendrites and synapses 
(synaptic alterations, re-orientation of dendrites and axons and modifications in branching 
structure) as well as the generation of new neuronal and glial cells, a process called neurogenesis 
and gliogenesis, respectively. Additionally, long-term potentiation and long term depression are 
known as functional neuroplastic changes. These physiological neuroplastic changes occur as a 
response to environmental stimuli, yielding functional alterations and gene expression alterations 
in order to achieve adaptation and further homeostasis(47,48). 
Neurogenesis is the process by which neural progenitors divide mitotically to generate 
new neurons. This neuroplastic process happens at least in two regions of the adult mammalian 
brain: the subgranular zone (SGZ) of the dentate gyrus (DG) in the hippocampus(49) and the 
subventricular zone (SVZ) lining the lateral ventricles(50).  
Particularly, the SGZ contains radial glial-like stem cells that express several markers, 
including GFAP (fibrillary acidic protein) and the intermediate filament nestin. These cells divide 
asymmetrically and produce Type-2 daughter cells, called transient amplifying progenitor cells or 
fast proliferating cells, which also express nestin and are much more proliferative than type-1 
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cells. Type-2 cells give raise to neuroblasts – type 3 cells. Type-3 cells are negative to GFAP and 
nestin but positive to doublecortin (DCX). This last stage correspond to transition between a slow 
proliferation neuroblast (which is exiting the cell cycle) to a postmitotic immature neuron that 
will migrate into the granule cell layer. These new cells will then became maturate into granule 
neurons with their axons being growth toward CA3 area of the hippocampus. After 2/3 weeks the 
cells express calbindin a marker of mature granule cells and after 4-8 weeks they are fully 
integrated in the pre-existing neuronal network(45,51,52). 
Several neuroplastic changes have been found in human samples. Hippocampal atrophy 
is a clear feature seen in meta-analyses studies of depressed patients(53). Additionally, 
postmortem studies of depressed patients showed reduced glial cell density in the prefrontal 
cortex, hippocampal DG and anterior cingulate cortex(46,54,55) as well as a decrease in neuronal 
size observed in the dorsal PFC and anterior cingulate cortex(55,56).  
Insights from animal models of depression have produced relevant findings regarding 
neural plastic changes induced by depression. Dendritic atrophy and spine loss was observed in 
neurons from the PFC and hippocampus of animal models of chronic stress (57). Also, a reduction 
in hippocampal neurogenesis was reported in animal models of stress exposure(58). Indeed, 
hippocampal neurogenesis was shown to be an important contributor for a sustained remission 
from depressive-like behaviour(59). The relevance of neurogenesis for depression is reinforced 
by the fact that antidepressant drugs take 3 to 4 weeks to exert their beneficial effects in patients, 
which corresponds to the same period for the maturation of adult born neurogenesis(45). Not 
only neuronal cells are affected in animal models of stress exposure. Indeed, chronic stress is 
known to induce a decrease in the proliferation of glial progenitor cells and reduce the number 
of GFAP-positive cells in the PFC and hippocampal DG. Additionally, impairments in astroglial cell 
morphology, metabolism and function are also observed(22,57,60,61).  
In fact, astrocytes have an active control on neuronal activity and synaptic plasticity ; this 
bidirectional communication between neurons and astrocytes is called ‘tripartite synapse’. In this 
process astrocytes are responsible for glutamate clearance from the synaptic cleft through 
transporters (EAAT1 and EAAT2); conversion of glutamate into glutamine (precursor of glutamate 
and GABA); release of trophic factors; metabolic support; intervention in the neuronal activity 
through variations of intracellular Ca2+, among other functions(33,62).  
Changes in the number or astroglial cells remodelling may affect the glutamatergic tripartite 
synapse through a decrease of extracellular glutamate clearance and subsequent activation of 
extrasynaptic glutamatergic receptors that will result in excitoxicity(22).  
To conclude, it was proved that both neuronal and glial neuroplastic alterations, could be 
reversible after ADs treatment(46,61,63). Treatment with SSRIs, MAOIs or TCA allows a fast 
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recovery of spine density as well as dendritic neuronal architecture which is associated with the 
remission from depressive-like behaviour(59,63,64). TCA and SSRIs are also capable of restoring 
neuro- and glio-genesis as well as BDNF levels(65)(51). 
Together, these neuroplastic reestablishments, potentiated by antidepressants, are crucial for 
the long-term remission from depression(66). 
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1.2 Validation criteria of animal models 
 
Nowadays, searching for better and accurate animal models is an effort of many 
researchers. In fact, a wide variety of animal models have been used to mimic the human 
depression. Many of the symptoms of depression (e.g. depressed mood, feelings of 
worthlessness, suicidal ideation) cannot be easily measured in laboratory animals because they 
involve higher cognitive abilities. However, by trying to improve the quality and the validity of the 
models it is possible to step-by-step get closer to the human disease in order to help finding new 
therapeutic targets as well as new insights about the pathology seen in the clinics(67,68). Due to 
this reason, animal models are fundamental and must be continuously improved. For that, several 
validation criteria must be fulfilled, aiming an intra- and inter-laboratory reproducibility - linked 
to the standardization power of the model. 
In 1969, William McKinney was the first to establish the minimal requirements for animal 
models of depression. These criteria include: an analogy between the symptomatology of human 
depression and what is observed in the animals; assessment of clear and objective behavioural 
changes that should agree between independent observers; treatment effective modalities in 
humans should reverse the changes observed in the animals; and the existence of reproducibility 
between investigators(69). 
 In 1984, Paul Willner refined the validation criteria proposed by McKinney. Most of the 
researches, working in the field of animal models of depression, rely on this last proposal by 
Willner that suggests 3 main validation criteria: predictive, face and construct validity. He 
described predictive validity as the capacity of the model to identify antidepressant treatments 
through the coherence between animal and human (un)successful agents as well as the model 
correlation with the success level seen in the clinics(70). Face validity is the resemblance between 
phenomenological similarities between the model and the disease through a coexistence of 
several aspects that are specific to depression. In other words, this criterion describes if the model 
mimics the diagnostic criteria of depression (core symptoms), while not referring to etiological or 
biological basis(68,70). Construct validity is the capacity to resemble the features and behavioural 
changes seen in human depression with a solid theoretical rational with unambiguous and 
homologous interpretation.  
Later, Willner updated these criteria for a concept that aligns the theoretical explanation 
of the human disease with the behaviour and biological dysfunctions seen in the animal model. 
Etiology is now included in this concept through the identification of the triggering factors that 
cause a depressive-like state, its characterization (unpredictability, chronic, etc) and its 
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correlation with biological processes involved in depression(12,68). Willner compared several 
animal models and stated that predictive validity seems to be the easiest criterion to achieve. 
Face validity and construct validity are the hardest criteria to get because their validation is filled 
in only a reduced number of models(70). 
More recently, in 2011, Belzung and Lemoine made a reformulation of these classic 
validation criteria. First, they referred the importance of internal validity which concerns the 
consistency of the experimental design (reproducibility, inter-observer reliability, randomization, 
blind experimentation and others) as well as the external validity that refers to the applicability 
of the results of a study on a sample to its extrapolation to the target population(68). Regarding 
the validation criteria, they introduced a different perspective of the validity concepts. However, 
the global outcomes being assessed remained the same, with an exception to homological 
validity, which is a totally new validity criteria. This criterion refers to the adequate choice of the 
animal species and of a particular strain. For instance, species more prone to display depressive-
like states at behavioural and biological levels are a better choice as an animal model than 
resilient species(68).  
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1.3 Animal models of depression~ 
 
1.3.1 Animal models based on (bio)chemical manipulations 
1.3.1.1 Chronic GC administration  
As the name implies, this animal model is developed by the chronic administration of GCs 
(known to be elevated in depression). These animals display some behavioural alterations similar 
to those observed in the clinics and also some molecular alterations including: anhedonia and 
learned helplessness phenotype(12); molecular and cellular changes are observed, like decreased 
BDNF expression in hippocampus(44), reduced neurogenesis, retraction of dendrites in CA3 
pyramidal neurons(71), increased CRF synthesis and secretion(12). These effects are reversed by 
chronic administration of antidepressants, like amitriptyline (a tricyclic antidepressant)(72). 
 
1.3.1.2 Stimulation of the immune system 
Up to 50% of patients with autoimmune diseases, such as multiple sclerosis, experience 
clinically significant depression. As it was previously stated, the activation of the inflammatory 
system seems to be correlated with depression onset. Moreover, cytokine alterations seem to 
elicit central monoamine and CRH changes(72). Induction of endotoxins and cytokines are models 
that show alterations at different levels, including brain neurochemistry changes, neuroendocrine 
and neuroimmune function alterations and behavioural changes – coincident with MDD 
alterations in humans. Additionally, the exposure to endotoxins or cytokines induce anhedonia 
phenotype, increase stress hormones and decrease locomotor activity and body weight. This is a 
low cost and easy-to-implement model but with a poor etiological validity. 
 
1.3.2 Genetic-related models 
1.3.2.1 Selective breeding 
 As stated before, depression requires genetic and/or environmental vulnerability. 
Selective breeding is based on genetic individual differences found in animals, an example is the 
Wistar-Kyoto (WKY) rat strain(73). This tool can be very useful however more work is needed to 
establish a line for a reliable model(74). 
 
1.3.2.2 Targeted overexpression or KO (knock-out) of specific candidate genes 
These are not considered formal animal models of depression but are helpful in same 
cases. For instance, 5-HT transporter knockout is used because it is the target of many 
antidepressants and as such it can give some insights about the molecular mechanisms. Also, the 
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knockout of tackykinin (NK1) has been associated with stress and anxiety, showing worse 
performances in the FST. 
HPA transgenic animals are also used in this context. These genetic mutant animals 
express irregular levels of GR, disturbing the normal negative feedback of the HPA axis.(67). 
Moreover, it is possible to test candidate-driven mutations, for example to alter a protein 
known to be implicated in depression and then characterize the resulting phenotype. This reverse 
genetics allows to start with a gene and study the backwards to identify its function(74). 
 
1.3.3 Lesion model 
Bilateral olfactory bulbectomy is a model of depression where the two lobes are ablated. 
This lesion leads to anosmia and most importantly to the loss of detection of pheromones which 
are crucial to reproductive behaviour, gender recognition, social dominance among other 
behavioural and physiological status of the animal(75). 
The olfactory system is part of the rat limbic region, and consequently this lesion will lead 
to a dysfunction of the cortical-hippocampal-amygdala circuit. More so, this model shows 
changes in behaviour, like impaired food-motivated behaviour, alterations in cognitive tasks (like 
morris water maze performance) and increased exploratory behaviour/open field activity. Also 
increased activity of the HPA axis is observed and some evidences claim that there are alterations 
of the immune system response. 
Importantly, this model shows predictive validity because chronic administration (not 
acute) of antidepressants can revert behavioural, endocrine, immune and neurotransmitter 
changes(75). However, this model lacks etiological validity because, in humans, the loss of 
olfaction does not produce self-rated depression(68). 
 
1.3.4 Animal models based on stress exposure 
Depression is a disease with a highly influence from environmental factors(16). Actually, 
models based on environmental stressors have great aetiological validity compared to the 
previously mentioned (brain lesions or biochemical manipulations)(12). 
 
1.3.4.1 Acute stress models  
These models are used as tools to rapidly screen putative antidepressant compounds. An 
example is the FST that consists of placing the animal in an inescapable cylinder tank filled with 
water. The animal starts struggling, swimming and climbing and eventually will stay immobile. It 
is measured the amount of time that the animal takes to stay immobile. One strength of the 
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model is the reduced errors in results measurement, however it lacks some validation criteria 
since the phenotype is reversed by acute administration of antidepressants(12,72).  
Still within the learned helplessness category, another approach is to expose the animals 
to inescapable electric shocks that allow them to develop a “helplessness” state. This happens 
because when animals are re-exposed to shocks, with an easy way out, they display a big latency 
or fail completely to escape. The major weakness is the same as above, successful response to 
acute drug treatment. Regarding positive aspects of the model, it is relevant to mention that rats 
develop alterations in sleep patterns; alterations in HPA axis activity; decreased number of 
synapses in the hippocampus; elevated CRF and corticosterone levels which all correlate with the 
human disease (74)(72). 
 
1.3.4.2 Chronic stress models 
Psychosocial stress (defeat or social isolation) 
This is a model with an interesting etiological validity. In social defeat the animal is 
repeatedly exposed to a dominant/aggressive animal. These animals show a reduced preference 
for sucrose in the sucrose preference test (SPT) and changes in the neuroendocrine system, which 
are reversed through chronic administration of antidepressants. Despite the fulfilment of the 
validation criteria, social behaviour is not well characterized in rodents. Also these models have 
poor reproducibility which reduced their application(72).  
 
Maternal care (maternal separation or prenatal stress)  
This is an early life stress model that produce neuroendocrine and behavioural changes. 
For example, it is seen that a bigger vulnerability to learned helplessness, persistent into 
adulthood, and hyperactive HPA axis. Their reproducibility is relatively good and successful results 
are shown in many different species from rodents to non-human primates. Antidepressants 
administration can reverse these abnormalities(72). 
 
Chronic stress exposure in adulthood   
These models are among the most valid ones(70). A crucial explanation for that is their 
naturalistic essence(74). As mentioned before, stress is one of the most consensual precipitating 
factors for depression.  
There are two widely used models of chronic stress: unpredictable chronic mild stress 
(uCMS) and chronic unpredictable stress (CUS)(76,77). The first one refers to a permanent 
exposure during 6 weeks to mild stressors in an unpredictable manner(77), whereas CUS protocol 
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is an intermittent exposure (1h per day) of more aggressive stressors during a 4 week period(76). 
Chronic unpredictable stress models reveal increases in plasma corticosterone levels, augmented 
serotonergic activity in the hypothalamus(76), alterations in aggressiveness, sexual behaviour as 
well as grooming deficits. These phenotypes are reversed by chronic administration of 
antidepressants either during the stress or as a post-stress treatment(72).  
Katz and colleagues were the first to develop a chronic mild stress procedure(78). Later, 
Willner developed a protocol based on this previous one but reduced the severity of the stressors 
to increase the resemblance with the human daily life stressors. Moreover, he considered 
reactivity towards a reward as the most relevant behavioural test to assess the phenotype onset, 
instead of locomotor activity previously used by Katz(79). This Willner procedure consists of a 
permanent exposure to a variety of mild stressors (e.g. overnight illumination; periods of food 
and/or water deprivation; cage tilt; change of cage mate, damp bedding), which must be changed 
every few hours(77) during  a period of several weeks(80). The diversity, unpredictability and mild 
intensity of the stressors are crucial aspects to prevent habituation to the protocol.  
Many applications are possible through the uCMS, this protocol can be used to discover 
new antidepressant drugs but also to provide insights about the pathophysiology of the disease 
(in both, cellular or molecular scale)(80). 
A closer look at uCMS model allow us to consider it as one of the most valid for the 3 
main criteria (predictive, face, construct and homological)(68,77), as it is explained below. 
A fulfilment of the predictive validity is observed because both behavioural and molecular 
alterations can be reversed through chronic administration of antidepressants from different 
classes (MAOs, SSRIs, TCAs)(5,64).   
Regarding face validity, it is possible to observe a decreased preference for a palatable 
sucrose solution(77,81), a diminished sexual behaviour, locomotor activity as well as alterations 
in sleep changes and self-care(77,79). Not only mood is impaired, cognition and anxiety are also 
affected in this model, resembling the multidimensional nature of depression in humans. Stressed 
animals show high anxiety levels and a worse performance in cognitive tests when compared to 
control animals(5). All together, these findings cover the main symptoms observed in humans 
and can be seen in this animal model.  
Construct validity is the theoretical rationale behind the alterations reported. For that, 
molecular and cellular analyses are needed. Indeed, increased activity in the HPA axis, which 
includes adrenal hypertrophy and corticosterone hypersecretion are observed in this animal 
model. Downregulation of hippocampal 5-HT1A receptors and hippocampal GR as well as 
reductions in frontocortical and hippocampal BDNF protein are also observed(80). Moreover, it 
is possible to observe abnormalities in the immune system(77), altered neuroplasticity 
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(neurogenesis  is reduced, dendritic length and morphology is impaired in several brain regions 
affected with depression)(22,66,82). 
Lastly, concerning the new criteria - homological validity, it has been reported that the 
sensitivity of the model varies between strains; however, the effectiveness of the procedure was 
reported in several different strains(68,79). Rats tend to be better models than mice in chronic 
mild stress models, and among the most used strains are Wistar Han and Sprague Dawley(79). 
Specific strains require specific adaptations in the procedures, for example Wistar Han rats only 
show robust measurements in SPT (anhedonic test) if the sucrose concentration is 2% and not 
1%(77).  
It is thus consensual that the model is valid in all criteria. However, some weaknesses can 
be pointed out: it is difficult to implement because it is executed manually what implies a labour-
intensive work; also it takes a long duration and it is space demanding(79). Some intrinsic aspects 
are also less favourable, like the use of artificial physical stressors (strobe lights or tilted cage) and 
the fact that non-treated animals reverse the phenotype in all the behavioural tests (except SPT) 
after 10 weeks of the uCMS. Despite several independent research groups had proven the 
reliability of the model his lack of reproducibility still remains a big concern and is seen as the 
biggest limitation(79). Some authors have suggested divergences in protocols, handling influence, 
disparity in conditions from the animal facilities as well as variations in animals. This last feature 
may account for different genetic backgrounds as well as different microbiota of each animal, 
known to play a role on susceptibility of animal models of chronic stress(79,83).  However, no 
clear evidences have emerged to explain the variability observed between laboratories. As such, 
one of the ways to improve the uCMS model is to increase standardization as well as to increase 
its effectiveness. 
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1.4 Research Objectives 
 
The main goal of this work was to finish the development of an automated equipment to induce 
depressive-like behaviour in rodents, based on the uCMS protocol and to do a pilot validation of 
the equipment. 
 
For that, the following objectives were defined: 
 Participate and supervise the construction of the equipment; 
 Test and improve the automated stressors individually (in order to better resemble the 
original manual method); 
 Validate the automated protocol using previously determined validation criteria: 
o Determine the induction of molecular, morphological and biochemical 
alterations in the automated model and compare with the manual protocol 
(construct validity); 
o Assess changes in several behavioural dimensions in the automated model and 
compare with the manual protocol (face validity); 
o Explore the pharmacologic ability to reverse the behavioural, molecular and 
cellular changes in the automated protocol (predictive validity) 
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2. MATERIALS AND METHODS 
 
The development of the equipment was performed in the context of a multidisciplinary 
team composed by a professional industrial designer, a mechanical engineer, an 
electrotechnical and computer engineer as well as neuroscience professors and researchers.  
The overall concept and design of the rack was already done when I joined the team, but the 
construction, optimization and implementation of the system was performed during my master’s 
thesis project with my direct intervention and active collaboration.  
Both, the equipment and the modified stressors were optimized and improved, first in 
empirical experimentations with several materials and architectures and, in later tests, through 
the use of animals for each individual stressor – from both models of chronic stress, CUS and 
uCMS. 
After this, all stressors from the uCMS protocol were put together to perform a complete 
protocol with animals. In order to perform the proposed study, two groups of animals were used: 
one group was submitted to the manual (traditional) protocol (uCMS) and another using the 
automated equipment (auCMS). A subset of animals from this latter group was submitted to 
fluoxetine treatment (treated auCMS). Also, a group of animals was kept in the accommodation 
room and only handled by the experimenters - the control group.  
Animals from all the groups were evaluated in order to measure behaviour, neuronal 
morphology in the hippocampal DG, corticosterone levels and cell proliferation. Details on the 
animals, treatments and tests are given along chapter 2. 
 
2.1 Animals  
2.1.1 Optimization phase 
Male Wistar Han (Charles-River Laboratories) Rattus norvegicus, with ~1 year of age and 
weighing 400-500 g, were kept 2 or 3 per cage, under 12h light: 12h dark cycles, at 22ºC, relative 
humidity of 55% and with food and water ad libitum. 
Some animals were used to test the adaptions of each stressor, individually: 3 animals for 
tilted-cage stressor; 1 animal for shaking stressor (additional); 3 animals for water-involving 
stressors; 6 animals for confinement stressor and also 3 animals for food deprivation followed by 
exposure to inaccessible food (additional). 
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2.1.2 Pilot-study 
Male Wistar Han (Charles-River Laboratories) Rattus norvegicus, with 2 months of age 
and weighing 300-400 g, were kept 2 or 3 per cage, under 12h light: 12h dark cycles, at 22ºC, 
relative humidity of 55% and with food and water ad libitum. 
Four groups were defined: 
A - 10 animals exposed to uCMS (uCMS) 
B - 6 animals exposed to auCMS without treatment (auCMS, NT) 
C - 6 animals exposed to auCMS with treatment (auCMS, T) 
D - 10 control animals (C). 
A, B and D were injected with a saline solution, whereas C was treated with an 
antidepressant (fluoxetine). In Group D, animals were not submitted to any chronic stress 
protocol. 
 
 
 
F igure 2. Timeline of the procedures: The induction of chronic stress was performed manually or automatically during 
6 weeks and in the last two weeks of this protocol fluoxetine was administered. After, depression induction protocols 
several analysis were performed. 
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2.2 Procedures  
The construction and optimization of the rack was performed in the lab facility. Only 
necessary tools were built outside the lab, in the mechanical facilities.  
After the construction of the equipment, it was necessary to adapt the individual 
stressors. For that, tests with animals were performed to achieve the most suitable configuration. 
The equipment was placed in the lab facility but outside the animal facility. So, tests that involved 
the use of animals in the equipment were performed outside the animal facilities (tilted-cage 
adjustments, shaking tests, and stressors performed with water) with the sacrifice of the animals 
at the end of the experiments. Tests that were not dependent of the equipment, like confinement 
or measurements of plasma CORT levels of animals, were tested in the animal facility.  
This process took around 6 months. The other 6 months were used to do a pre-test of 
the automated uCMS protocol and its further analysis. 
In Fig 2, it is possible to have an overview of the whole sequence of the procedure. Below, 
there is a detailed description of the induced protocol and the following analysis. 
 
2.2.1 Manual unpredictable chronic mild stress 
A modified version of Willner’s uCMS protocol was applied(5). The variety range of 
stressors included confinement to a restricted space, placement in a  tilted cage (~30°/45°), 
housing on damp bedding during the night, overnight illumination, food deprivation followed by 
exposure to inaccessible food, water deprivation followed by empty bottle exposure, reversed 
light/dark cycle, exposure to strobe lights, overcrowding, cage switch and startle noise. Animals 
are randomly and uninterruptedly exposed to the stressors during 6 weeks.  
In general, our protocol had 4 stressors each day and 1 stressor in the night. Stressors for 
the day did not exceed the following time period: restricted space (2h), tilted cage (4h), 
inaccessible food (1h), empty bottle (1h), strobe lights (4h), overcrowding (3h), cage switch (2h) 
and startle noise (4h).  
The intensity level (e.g the time of exposure/ aggressiveness of the stressor/ double 
stressors) increased over the development of the protocol(5). Double stressors were used in both 
night and day period; they included: water deprivation with illumination, food deprivation with 
tilted cage, tilted cage with reversed light cycle, food deprivation with wet bed and water 
deprivation with strobe lights. 
Control animals were gently handled every week throughout the 6 weeks protocol.  
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2.2.2 Prototype  
The traditional method to perform this protocol is manual. Animals are housed in a rack 
and every 2 or 4 hours the experimenter needs to change the stressor, with the exception of the 
night stressors. Through the development of this novel equipment it is possible to apply uCMS, 
in an automated manner with all the cages simultaneously performing the stressors.  
The structure of the equipment was designed based on a traditional rack. This automated 
rack is connected to a computer where it is possible to upload the scheduled protocols with the 
intended stressors as well as the lights state. Because the stressors incorporated into the 
automated prototype are based on the same stressors used in manual protocols, the outcomes 
may be preserved.  
The equipment was designed for 24 cages (3 animals per cage), which enables the 
manipulation of 72 animals at the same time. 
The patenting of this prototype is in process of submission.  
 
2.2.3 Automated unpredictable chronic mild stress 
This equipment will enable to perform the same manual stressors of a traditional uCMS 
protocol but in an automated way. The protocol was uploaded into the computer (connected to 
the automated rack) and it ran over 6 weeks. 
Stressors were divided in 3 categories: totally automated (TA), partially automated (PA) 
and non-automated (NA), as it is deeply explored in the Chapter 3 (results). 
TA stressors are the ones exclusively performed by the rack, without the intervention of 
the operator and include placement in a tilted cage (45o), housing on damp bedding during the 
night, overnight illumination, reversed light/dark cycle and startle noise. PA stressors refer to 
confinement to a restricted space, a stressor that has undergone some changes in order to be 
user-friendlier. Finally, NA stressors are those that depend exclusively from the intervention of 
the experimenter and for that were kept as in the manual protocol; that is the case of food and 
water deprivation followed by exposure to inaccessible food/water, overcrowding and cage 
switch.  
 
2.3 Drugs administration 
Fluoxetine (SSRI) was the antidepressant chosen to test the reversion of the 
symptoms(84) because it is one of the most widely used first-line therapy in the clinics and it was 
already shown to be able to induce recovery from uCMS in depressive-like rats(5,59). 
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The treatment groups received an intraperitoneal injection (10mg/kg, Kemprotec) every 
day during the last two weeks of the uCMS protocol, ensuring its action during all the behavioural 
tests period(5). The remaining groups (group A, B and D) received an I.P. injection of saline 
solution. 
 
2.4 Behavioural Tests  
In order to validate the newly developed automated equipment all animals (controls, 
uCMS-exposed, and auCMS-exposed) were subjected to a behavioural test battery which 
encompassing tests to assess the three major behavioural domains affected in depression. 
Behavioural tests were performed at the end of the uCMS protocol starting on week 6. 
To evaluate mood improvements three behavioural tests were used, the SPT and the sweet drive 
test (SDT)(85) to evaluate anhedonia as well as FST(5) to evaluate behavioural despair. In order 
to analyze changes in cognition we used the novel object recognition (NOR) test (5). Anxiety-like 
behaviour was evaluated using the novelty supressed feeding (NSF)(5) test. 
The tests were performed in the following order SPT-SDT-NOR in the 6th week and NSF-
FST in the 7th week as it is represented in Fig 2.  
 
2.4.1 Sucrose preference test 
Sucrose Preference Test (SPT) was used to assess anhedonic behaviour of the animals 
exposed to the uCMS protocol(5). Animals were allowed to habituate to the sucrose solution (2% 
m/v) one week prior to the uCMS protocol in a three-trial paradigm in order to establish the 
baseline values for sucrose preference. For each assay, animals were food- and water-deprived 
for 12h during non-active period (light on/diurnal period). The room was cleaned with ethanol 
96% and the test was performed under dim illumination. Each animal was placed individually in a 
cage, covered with the grid and the lid. Two pre-weighted bottles were placed in opposite sides 
of the cage: the one containing a 2% (m/v) sucrose solution in the food site and the one with tap 
water placed in its original site. 
Sucrose preference was calculated by the following formula: sucrose preference = 
[(sucrose consumption / Total consumption) x 100]. Anhedonia was defined as a reduction in 
sucrose preference in relation to the baseline levels(5).   
 
2.4.2 Sweet drive test 
SDT was also used as a measure of anhedonic behaviour, as previously described(85). 
Animals were pre-habituated to sweet pellets (3.77 kcal/g; Honey Cheerios®; Nestlé Portugal S.A., 
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Portugal) in the day before the first trial, overnight. Before each trial, animals were food-deprived 
for 12h during the light (non-active period) and the exposure to stressors was suspended. The 
test apparatus consisted of a black acrylic enclosed arena (82 cm x 44 cm x 30 cm) divided by 
transparent and perforated walls into 3 closed chambers and one pre-chamber in which the 
animal is initially placed. This pre-chamber is connected to a middle chamber by a trap door. 
Once the animal crossed the trap door, this door closes and the animal is allowed to 
explore de other 2 chambers, one on the left and one on the right side of the apparatus. Part of 
the apparatus was also a transparent acrylic lid to ensure surroundings noise-reduction.  
When initiating a new trial, the SDT arena was carefully cleaned with ethanol 10%. A total 
of  20 pellets of regular food (3.60 kcal/g; Certificate standard diet 4RF21; Mucedola, S.R.L., Italy) 
were positioned in the corner of the left chamber and 20 sweet pellets were placed in the corner 
of the right chamber. The animals were allowed to explore freely for 10 minutes (min) per trial.  
At the end of the trial, pellets consumption was determined and preference for sweet 
pellets was determined as follows: preference for sweet pellets (%) = Consumption of Sweet 
Pellets (g) / Total Food Consumption (g) × 100. 
 
2.4.3. Novel object recognition 
Cognitive function was assessed through the NOR at the 6th week of the uCMS protocol. 
For this purpose, a black acrylic box (50x50x150cm) with an open field space (51x51x39.5cm) and 
illuminated with a white lamp (100-140 lux) was used (86–89).  
The test was divided in 4 days. On the first day the animals were allowed to explore the 
test apparatus without any object inside, during 10 minutes. On the second day, two identical 
objects were placed in the back left and right corners of the apparatus and the animal was able 
to explore them during 10 min. On the third day, the object in the left corner was replaced by a 
novel object for 3 min in order to check long-term memory. Lastly, on the fourth day, animals 
were tested for short-term memory. The previous objects were changed for two novel equal 
objects and the animal was allowed to explore for 10 min. Within an interval of approximately 
one hour, the left object was replaced by a new object and the animal was allowed to explore 
once again, for 3 min.  
Trials were video-recorded and analyzed in the Etholog (vs.2.2) software. The 
discrimination index (D) was calculated by the following formula: D = (N-F)/(N+F); being N the 
time spent exploring the Novel object and F the time spent exploring the Familiar object.  
The exploration of an object was considered when the animal is directing the nose to the 
object at a distance of less than 2 cm or touching it with the nose. 
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2.4.4 Novelty supressed feeding 
NSF was used to measure anxiety-like behaviour at the 7th week of the uCMS protocol. 
For this test, animals were food deprived for 18h and then placed for 10 min in an open -field 
arena covered with bedding, containing a single food pellet at the centre. When reaching the 
pellet, the animal was immediately placed individually in the home cage and allowed to feed a 
pre-weighted regular food pellet for 10 min.  
The latency to feed in the open-field arena was used as an anxiety-like behaviour 
index(5,85). 
  
2.4.5 Forced Swimming Test  
Learned-helplessness was evaluated through the FST (85) and was conducted at week 7 
of the uCMS protocol. In the test, animals were placed in transparent glass cylinders filled with 
water (25°C; 50cm of depth) and submitted to a 5 min pre-test session, 24h before the assay. The 
test session had a duration of 5 minutes.  
Trials were video-recorded and immobility time was measured through the Etholog 
(vs.2.2) software. Learned-helplessness was defined as an increase in the immobility time. 
 
2.5 Plasma corticosterone level  
The blood samples were collected from all animals, in the 6th week (at 8 p.m and 8 a.m), 
kept on ice and then centrifuged immediately for 15 min. The obtained plasma was kept at −80 
°C until analysis.  
Corticosterone levels were measured using a commercially available kit (Corticosterone 
ELISA kit –ABCAM, ab108821).  
 
2.6 BrdU Immunostaining  
In the last day of the protocol, animals were given a single intraperitoneal injection of 
Bromodeoxyuridine (10mg/kg, Sigma-Aldrich). BrdU is a thymidine analogue that incorporates 
into DNA during the S-phase of the cell cycle.  
Twenty-four hours after the injection, animals were deeply anaesthetized with sodium 
pentobarbital (Eutasil, Ceva Saúde Animal) and transcardially perfused with saline solution 
followed by ice cold 4% paraformaldehyde (PFA, ThermoScientific). After, brains were removed 
and post-fixed in 4% PFA. Twenty-four hours later, brains were washed with phosphate-buffered 
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saline (PBS) solution and transferred into a 30% sucrose solution until they sank. Then, they were 
embedded in OCT compound (Thermo Scientific) and frozen using liquid nitrogen and 2 -methyl-
butane. Finally, brains were frozen at -20ºC until being cut in a cryostat. 
Coronal sections (20µm) were cut in a cryostate, extending over the entire length of the 
hippocampus and after stained for BrdU (1:100; anti-rat, Dako)(52).  
Briefly, tissue sections were fixed with PFA 4% and washed with distilled water. Antigen-
retrieval was performed with a citrate solution for 20 min in the microwave. Next, sections were 
washed with distilled water. Permeabilization was made with PBS-Triton for 10 min followed by 
acidification with HCl for 30 min. Then, the slices were washed with PBS-Triton, and were after 
incubated overnight with the primary antibody. Finally, a secondary antibodies incubation for 2h 
(1:1000; anti-rabbit Alexa-fluor® 494; Life Technologies, Thermo Fisher Scientific) was performed 
followed by slides washing with PBS-Triton. At the end, all sections were stained with 4’,6- 
diamidino-2-phenylindole (DAPI; Invitrogen; 1:200 in PBS-Triton) for 10 min. 
For each animal, BrdU positive cells within the SGZ of the DG were counted (3-8 brain 
sections per animal) using a fluorescence microscope (BX61, Olympus, Hamburg, Germany). The 
corresponding DG areas were determined using a stereologic microscope (Bx51, Olympus, Tokyo, 
Japan)(52). 
 
2.7 Morphological analysis  
For the three-dimensional morphometric analysis, animals were deeply anaesthetized 
with pentobarbital (Eutasil, Ceva Saúde Animal) and transcardially perfused with 0.9% saline. 
Then, brains were removed and immersed in Golgi-Cox solution for 21 days; transferred to a 30% 
sucrose solution and cut on a vibratome. Coronal sections (200µm) were collected in a 6% sucrose 
and blotted dry onto gelatin-coated microscope slides. They were subsequently alkalinized in 
18.7% ammonia, developed in Dektol (Kodak), fixed in Kodak Rapid Fix, dehydrated and xylene 
cleared before coverslipping. 
Dendritic arborization was analyzed in the dorsal dentate gyrus. For each selected 
neuron, all branches of the dendritic tree were reconstructed at 1000x (oil) magnification using a 
stereologic microscope (Zeiss) and Neurolucida software. For each animal, a minimum of 8 
neurons were studied and total dendritic length was determined(64). Three-dimensional Sholl 
analysis was used to evaluate the arrangement of the dendritic material; for this, the number of 
dendritic intersections with concentric spheres positioned at radial intervals of 20  μm was 
determined(63). 
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2.8 Statistical analysis  
Statistical analyses was performed using GraphPad Prism 6 software (GraphPad Software, 
Inc.) 
One–Way analysis of variance (ANOVA) was used to compare between CT group (D), 
auCMS untreated group (B) and uCMS group (A). If H0 was rejected, differences between groups 
were determined by Tukey’s multiple comparison test.  
Student’s t-test was used to test differences between auCMS treated (C) and non-treated 
(B) animals. 
 Two-way analysis of variance (ANOVA) was used to assess differences between CT group 
(D), auCMS untreated group (B) and uCMS group (A) specifically for CORT levels and sholl analysis 
(morphology). If H0 was rejected, differences between groups were determined by Sidak’s 
multiple comparison test. 
 Statistical significance was accepted for P≤0.05. Data is presented as group mean ± 
standard error of the mean (SEM).   
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3. RESULTS 
3.1 Rack development  and optimization 
In this section I will start by presenting the steps in which I was involved during the 
construction phase of the prototype. Then, I will approach the optimization of the mechanisms 
and issues that were raised during the implementation of the stressors. To conclude, I will focus 
on the behavioural, cellular and molecular analysis that result from the pilot study using a small 
cohort of rats. 
 
3.1.1 General features 
This equipment (Fig 3) presents several features that allow overcoming some of the 
weaknesses of the uCMS protocol. Moreover, the equipment is controlled and programmed 
through a computer present in the same room (Photo 1).  
 
 
 
F igure 3. Representative scheme of the automated prototype for uCMS. 
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Photo 1.  Control computer linked to the equipment. 
 
3.1.2 Mechanical details 
This is a labour intensive protocol, in particular the manipulation of the cages during 
some of the stressors. To overcome this issue a metallic structure bounded to the rack and to the 
lid of the cages, with the aim of opening 3 cage lids at once, was developed.  
This feature (Photo 2) is a user-friendly structure very useful to stressors that involve 
manipulation of the cages by the experimenter, particularly to perform stressors of 
deprivation/inaccessibility of food or water as well as to perform our proposed confinement 
stressor. Also, it is helpful for stressors dependent from animals’ manipulation, like overcrowding 
or switch-cage.  
 
 
 
Photo 2. Mechanical feature of the equipment – opening three cages at once. 
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3.1.3 Stressors categories 
Regarding the stressors, they were divided in 3 categories: totally automated (TA), partially 
automated (PA) and non-automated (NA), as mentioned in the Chapter 2 (methods). 
Below, there is a list of the stressors that are part of the uCMS protocol, characterized by 
their categories: 
 
         Table 1. Stressors of the model divided by 3 main categories. 
 
 
3.1.4 Totally Automated stressors 
Totally automated stressors are performed exclusively by the rack without the 
experimenter intervention. This category encompasses motor-dependent stressors (A), water/air 
supply-dependent stressors (B), lights-dependent stressors (C, D, E) and sound-dependent 
stressor (F). 
 
Tilted-cage (A) 
In the original protocol the cages are placed on the floor or in a table with a grid below 
them to enable their inclination.  
Our automated equipment has a motor incorporated to allow the implementation of 
some stressors which is the case of tilted-cage (Photo 3). The choice of the angles must be 
previously programmed, meaning that different angles cannot be incorporated into the same 
protocol.  
 
A. Tilted cage (approximately 45º) 
B. Housing on damp bedding during the night
C. Overnight illumination
D. Inverted light/dark cycle
E. Exposure to strobe lights 
F. Startle noise
G. Food deprivation followed by exposure to inaccessible food
H. Water deprivation followed by exposure to an empty bottle
I. Overcrowding
J. Cage switch
PA K. Confinement to a restricted space
TA
NA
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Photo 3. Mechanical feature of the equipment – tilted cage stressor 
 
Shaking (additional stressor - CUS protocol) 
This motorized system was also developed to perform shaking, which is a stressor from 
the CUS protocol. Although this stressor is not part of the uCMS protocol (it was not included in 
the set of experiments of the pilot study described in this work), it was introduced to extend the 
features range for future work.  
During the tests made to refine the equipment, it was observed that shaking speed was 
not uniform for all the rack lines. After analysing several causes, we realised that the speed 
variations were due to a mechanical imperfection (the cam did not rotate closest to the Teflon 
board) and as such, the problem was solved by putting a metallic ring (Photo 4) near to the 
spring’s system.  
 
 
Photo 4. Mechanical detail – metallic ring for the shaking movement correction 
 
Damp bedding (B) 
In the manual protocol, water is added to the cages one by one. On the other hand, this 
automated rack enables to provide a uniform and simultaneous water supply to each cage 
through a tube system linked to the cage lids (Photo 5). The quantity of water released can be 
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programmed. In order to get this water/air supply system operational an extensive process of 
optimization was made.  
First, we had to find the most suitable diameter for the tubes, capable of supplying water 
until the most high and distant corner of the rack as well as the optimal material for the tubes’ 
system. After a few empirical experiments we observed that 16mm was the minimum tube 
diameter to achieve an equal water distribution. Regarding the materials’ choice, a low-density 
polyethylene tube was selected, based on a drop wise irrigation. This material is not toxic or 
harmful to the animals and does not erode with water. Nevertheless, other liquids should not be 
used inside the tubes.  
To prevent the junctions of the tubes of pouring water, some clamps (Photo 6) were used 
for waterproofing the system 
Additionally, the system has also the particularity to supply air (using the same system of 
tubes used for water). Experiments were made to find the most suitable air pressure to resemble 
hot air stream in the CUS protocol. We concluded that each cage needs to have at least 6 bars of 
pressure to perturb the animals similarly to the manual stressor. Although, at first this air system 
was built as an independent stressor, to mimic hot air stream, after some experiments this aim 
was abandoned. For now, the air will only be used to purge the system after stressors  involving 
water. The objective is to dry the tubes after each use to prevent the growth of fungi and bacteria. 
 
 
 
Photo 5. Water/air supply system – wet bed or cold water stressor 
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Photo 6.  Detail of the water tubs – clamps to seal the system 
Regarding the architecture of the structure, some attempts were made and a final structure 
was found. An approach that divides the structure in two (1 st, 2nd line and 3rd, 4th line) appeared 
to be the one that minimizes the water volume error for each cage. Even though, to equalize the 
volume of water per cage some mini taps were introduced near the tube exit to regulate the 
water flow per cage (Photo 7). 
It must be highlighted that, in the beginning of each protocol, the system needs to be pre-
tested and mini-taps must be adjusted, in fact the pipes need to be filled with water to achieve 
equal volumes of water. For that, before each protocol a priming process must be performed to 
fill the tubes, otherwise the pre-defined times will not lead to a standard volume. 
  
 
Photo 7. Detail of the water tubs – mini taps to control water volume 
 
Cold water (additional stressor - CUS protocol) 
Our system provides the chance to perform another stressor from the CUS protocol - cold 
water exposure. In this stressor, animals have their paws immersed in cold water in a cage without 
bedding. This stressor was not included in the pilot validation work. However it just require a 
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definition of the exact quantity of water to perform this stressor and its programming in the 
system. 
 
Light-dependent stressors 
Several stressors (C, D, E) are light-depend. Lights and stressors settings must be 
programmed as separate elements in the software, since most of the times they are used in 
parallel with other stressors; for example inverted light-cycle with tilted cage. (Photo 8). For the 
E stressor is was necessary to incorporated strobe lights in the system (Photo 9). 
 
 
Photo 8.  Software that controls the equipment 
 
 
Photo 9. Accessories linked to the equipment – strobe lights stressor 
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Sound-dependent stressor 
Lastly, to perform the startle-noise stressor (F) a sound-system was linked to the rack and 
put under the software’s control (Photo 10). 
 
 
Photo 10. Accessories linked to the equipment – startle noise stressor 
 
3.1.5 Partially automated stressors 
Confinement to a restrict space 
Partially automated stressors are not performed by the rack but were modified 
comparing to the manual protocol to reduce the intervention of the experimenter.  
 In the manual protocol, confinement is performed by putting 3 animals in a plastic box; 
in this alternative version of the protocol, an acrylic object was designed to reduce the space of 
the cages and confine the animals (Fig 4). 
In the development of this stressor, it was necessary to measure the volume of the plastic 
boxes used in the manual protocol (3L). Our device was designed and built to try to produce the 
same effect of the manual stressor. 
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              Figure 4. Demonstration of the operation mode of our space restrictor. 
 
 
Food deprivation followed by exposure to inaccessible food (additional stressor) 
In the original protocol, to perform this stressor the food is removed from the cages by 
the experimenter at the end of the day and in the morning after a container is placed in the grid 
to allow the animals to smell but not to eat the food (during a period of 1 hour).  
To try to reduce this work, an accessory was constructed to replace the food deprivation 
stressor (G). A food container was built to allow an easy access or restriction of the food just by 
changing its position. 
The different versions of this accessory will be further explained (Photo 12). 
 
3.1.6 Non-automated stressors 
Non-automated stressors are not performed by the equipment; instead they are 
completely dependent on the experimenter’s intervention. These stressors are G, H, I and J, which 
are described in Table 1  and were not modified compared to the traditional protocol. 
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3.2 Optimization of individual stressors with animals  
At this point, stressors were already developed. Since some of them suffered several 
alterations, it was necessary to guarantee that the effect provoked in the animals was similar to 
what happens in the manual protocol (e.g. hypercortisolemia). For that purpose modified 
stressors were tested individually with rats. 
 
3.2.1 Total Automated stressors 
Tilted-cage (A) 
In the manual protocol tilted cage is performed with around 30 o. Because our prototype 
gives us the possibility of having an inclination of more than 60  o(5), it was necessary to test with 
the animals different inclinations to find the most proper one, more precisely, the inclination that 
induces discomfort to the animals. We chose ~45 o, a bit higher than what is used in the manual 
protocol. This inclination increase was made to improve the efficacy of the procedure (since this 
stressor was really mild) without compromising it.  
 
Shaking (additional stressor - CUS protocol) 
After adjusting the shaking speed a first trial with animals was performed. The stressor 
was too mild to disturb the rats and the movement needed to be more violent to mimic the 
manual stressor. For that, we decided to build a bigger cogwheel to achieve the required speed 
(this solution was chosen instead of changing the cams because it would take a more mechanical 
expertise and it would be more expensive).  
 
Damp bedding (B) and cold water (additional stressor - CUS protocol) 
A test with the animals was made to find the quantity of water needed for the two 
stressors: cold water for CUS and wet bed for uCMS. The time needed to achieve the proper water 
volume is dependent on the water pressure, the tube diameter and technical details (valve stays 
open 1~2s after the plug turns off).  
In the case of wet bed, 1000 mL was the necessary volume (corresponding to t=39 s) to 
fill in the cages containing bedding. For cold water, for the CUS protocol, 500mL of water 
(corresponding to t=17 s) were enough, as the cages do not contain bedding. 
After the development of the water system the software was programmed and 4 
different possibilities for water supply were included: 500mL=17s, 750mL=27s; 1000mL=39s and 
1200mL=46s, to make the system more flexible.  
 
Chapter 3. Results 
39 
 
3.2.2 Partial automated stressors (accessories) 
Confinement to a restricted space 
Two space restrictor versions were developed, one in metal and another in acrylic. 
Preliminary tests with animals revealed that the metal version could hurt the animals and as such 
we chose the acrylic version. Adding to that, the metal devices were heavier and less practical 
(Photo 11). Additionally, some alterations were necessary to get closer to the manual stressor. 
The number of the “respiratory-holes” was reduced to better mimic the original conditions and 
to diminish the price of the device. The size of the “manipulation-holes” was also redefined to 
avoid conflict with the water bottle placement (Fig 5).  
The big advantage of this accessory is to reduce the time spent to perform the test and 
avoid having to manipulate the animals during the procedure. This new process takes 30 seconds 
to put one line of the rack (6 cages - 18 animals) in the confinement stressor. On the other hand, 
the time needed to do the same stressor in a manual way is 360 seconds.  
To assess the effect of using a plastic box (manual confinement) or an acrylic restrictor 
(automated confinement) on the animals, acute CORT levels were measured after the procedure. 
CORT was collected immediately after the exposure to the acute stress, from 6 animals: 3 in the 
cage exposed to the manual stressor and the other 3 in another cage exposed to the automated 
stressor. 
Results did not show statistical differences between the two procedures (t(10)=0.1972, 
p=0.8476), suggesting that the 2 procedures were able to induce the same kind of physiological 
response, as illustrated in Fig 6. 
This last stressor was the only one to have an assessment of the CORT levels because it 
was the only stressor that had a completely different action mechanism. The other stressors were 
not significantly different to provoke changes in the animals’ response and so, it was not 
necessary. 
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Photo 11. Accessories for partial automated stressors – space restrictor in metal (left) and in acrylic (right)  
 
 
 
F igure 5. Scheme of two versions of partial automated stressor – space restrictor, from the oldest (left) to the new 
(right). 
 
Chapter 3. Results 
41 
 
 
F igure 6. Corticosterone levels measured in the serum of rats exposed to a manual confinement procedure and to an 
automated confinement procedure. Abbreviations: CORT, corticosterone; Automated, exposure to an automated 
stressor; Manual, exposure to a manual stressor. 
 
Food deprivation followed by exposure to inaccessible food (additional stressor) 
In order to build the food restrictor, some prototypes of this accessory were designed. 
None of the versions let the animals feed properly, first because the material was thick and the 
distance between the grid and the restrictor was too big. Then, because the structure itself 
covered the access to food (Photo 12). A final version was developed, but unfortunately this last 
version was not ready at the time of the pilot study. Future work is being developed to test the 
final version of this stressor. Due to this, this stressor was performed just like in the manual 
protocol in the pilot study presented in this thesis.  
 
 
Photo 12. Accessories for partial automated stressors – food restrictor from the oldest to the new version (left to right). 
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3.3 Pilot study: Testing an uCMS protocol with animals in the automated rack  
After development and optimization of the equipment and the stressors, a 
comprehensive study was made. For that, we performed a complete uCMS protocol (pilot study) 
and analyzed several dimensions to validate the presented prototype. 
 
3.3.1 Behaviour dimensions 
The uCMS protocol typically produces deficits  in 3 behavioural dimensions commonly 
affected in depression: anxiety, mood and cognition(5). To understand the validity of this new 
approach it is crucial to do an extensive analysis of the dimensions affected in order to compare 
with the manual protocol. 
 
Mood  
SDT and SPT were performed to measure anhedonic behaviour (Fig 7 and Fig 8, 
respectively) in the 6th week. 
In the SDT, CT groups were compared to uCMS and auCMS animals (F(2,20)=3.930, 
p=0.0364); uCMS presented significantly lower preference for sweet pellets comparing to control 
group (p=0.0353), the automated stress also caused a decrease in the sweet preference however 
not reaching statistical significance (p=0.2162). This decrease was tendentiously reverted by 
antidepressant treatment (t(7)=1.205, p=0.2673; Fig 7).  
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F igure 7. Assessment of anhedonic behaviour through the SDT at the 6th week of the uCMS protocol. The groups 
exposed to this anhedonic behavioural test were control animals, animals exposed to the uCMS and auCMS protocols 
as well as auCMS animals treated with fluoxetine. Abbreviations: CT, control; uCMS, manual stressed animals injected 
with vehicle; auCMS, automated stressed animals injected with vehicle; auCMS+FlX, automated stressed animals 
treated with fluoxetine. Data is presented as mean ± SEM. * p<0.05; ** p<0.01; **** p<0.0001. n= 4-10 animals per 
group. 
In the SPT, only uCMS produced a reduction in the sucrose preference when compared 
to the CT group (F(2,23)=5.858; CT vs uCMS: p=0.0084 and CT vs auCMS: p=0.8149). Treated 
animals show no difference in their sucrose preference when comparing to the auCMS group 
(p=0.7045 in t(9)=0.3915; Fig 8).  
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F igure 8. Assessment of anhedonic behaviour through the SPT.. The groups exposed to this anhedonic behavioural test 
were control animals, animals exposed to the uCMS and auCMS protocols as well as auCMS animals treated with 
fluoxetine. Abbreviations: CT, control; uCMS, manual stressed animals injected with vehicle; auCMS, automated 
stressed animals injected with vehicle; auCMS+FlX, automated stressed animals treated with fluoxetine.  Data is 
presented as mean ± SEM. * p<0.05; ** p<0.01; **** p<0.0001. n= 5-10 animals per group. 
 
Learned-helplessness was evaluated through the FST at the 7th week. In this test (Fig 9), 
both uCMS and auCMS-exposed animals spent more time immobile when compared to controls 
(F(2,23)=3.518, P=0.0464); auCMS-exposed animals show a worse performance comparing to the 
CT group (p<0.0001), however uCMS could not reach statistical significance (p=0.1680). Treated 
auCMS-exposed animals did not show differences in immobility time when compared to the non-
treaded auCMS group (t(10)=0.4087, p=0.6914; Fig 9). 
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F igure 9. Assessment of mood dimension through the FST. The groups exposed to learned helplessness were control 
animals, animals exposed to the uCMS and auCMS protocols as well as auCMS animals treated with fluoxetine. 
Abbreviations: CT, control; uCMS, manual stressed animals injected with vehicle; auCMS, automated stressed animals 
injected with vehicle; auCMS+FlX, automated stressed animals treated with fluoxetine.  Data is presented as mean ± 
SEM. * p<0.05; ** p<0.01; **** p<0.0001. n= 6-10 animals per group. 
 
Cognitive function  
Cognitive function was assessed through the evaluation of short-term memory (STM) and 
long-term memory (LTM) in the NOR test at the 7th week. When compared to CT animals, STM is 
impaired in both uCMS and auCMS-exposed animals (F(2,23)=0.2924, p=0.7492), but only the 
auCMS group reaches statistical significance (CT vs uCMS animals: p=0.0943; CT vs auCMS: 
p=0.0458; Fig 10). Animals exposed to auCMS and injected with fluoxetine (Fig 10) did not 
revealed any differences regarding cognitive impairments (t(8)=0.1029, p=0.9206) in STM. 
Regarding LTM, a decrease in discrimination index was also observed in the uCMS and 
auCMS-exposed animals when comparing to the CT group F(2,23)=0.1530, p=0.8590; Fig 11). 
Statistical differences were found between CT and auCMS groups (CT vs uCMS: p=0.1203; CT vs 
auCMS: p=0.0015). The auCMS treated animals showed a tendency to have a higher 
discrimination index compared to non-treated animals (t(8)=0.9734, p=0.3589; in Fig 11).  
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F igure 10. Assessment of short-term (ST) memory. The groups subjected to the NOR test were control animals, animals 
exposed to the uCMS and auCMS protocols as well as auCMS animals treated with fluoxetine. Abbreviations: CT, 
control; uCMS, manual stressed animals; auCMS, automated stressed animals injected with vehicle; auCMS+Flx, 
automated stressed animals treated with fluoxetine. Data is presented as mean ± SEM. *p<0.05; ** p<0.01. n= 4-10 
animals per group. 
 
F igure 11. Assessment of long-term (LT) memory. The groups subjected to the NOR test were control animals, animals 
exposed to the uCMS and auCMS protocols as well as auCMS animals treated with fluoxetine. Abbreviations: CT, 
control; uCMS, manual stressed animals; auCMS, automated stressed animals injected with vehicle; auCMS+Flx, 
automated stressed animals treated with fluoxetine. Data is presented as mean ± SEM. * meaning p<0.05; ** meaning 
p<0.01. n= 4-10 animals per group. 
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Anxiety-like behaviour 
To conclude, anxiety-like behaviour was assessed through the NSF test at the 7th week. 
Control animals displayed lower latency to feed when compared to both uCMS and auCMS-
exposed animals (F(2,23)=0.4879, p=0.0774; CT vs uCMS: p=0.0105 and CT vs auCMS: p=0.0005; 
Fig 12). In line with the other tests, fluoxetine treatment could partially revert the phenotype of 
the auCMS-exposed animals, although not reaching statistical significance (Fig 12; t(10)=1.817, 
p=0.0992). 
 
 
 
F igure 12. Assessment of anxiety-like behaviour. The groups subjected to the NSF test were control animals, animals 
exposed to the uCMS and auCMS protocols as well as auCMS animals treated with fluoxetine. Abbreviations: CT, 
control; uCMS, manual stressed animals; auCMS, automated stressed animals injected with vehicle; auCMS+FLX, 
automated stressed animals treated with fluoxetine. Data is presented as mean ± SEM. *P<0.05; ***P<0.001. n= 6-10 
animals per group. 
 
3.3.2 Corticosterone levels 
Previous studies have shown that exposure to uCMS induces a disruption in the HPA Axis 
(26). Therefore, corticosterone levels in the blood serum are a valuable predictor of stress 
reactivity in the animals. Rats present a corticosterone peak at the beginning of their activity 
period that corresponds to the night period. Moreover, chronic stress exposure is known to 
disrupt the circadian pattern of corticosterone secretion (90,91). 
At the 6th week of the uCMS protocol, corticosterone levels were measured. Differences 
between the hormone levels in nadir and zenith were assessed (F (2, 46) = 9.810, p=0.0003). 
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Control animals presented a functional circadian regulation of the corticosterone production 
(Nadir vs Zenith: p=0.0026). On the other hand, a disruption of the circadian rhythm of 
corticosterone production was observed for the two protocols of chronic stress: uCMS and 
auCMS (CT vs uCMS: p=0.0342 and CT vs auCMS: p=0.9765). 
Animals exposed to uCMS and auCMS showed increased basal levels of corticosterone 
(nadir, N) when compared to CTs; although in the case of auCMS the differences did not reach 
statistical significance (F(2,23)=8.126, p=0.0021; CT vs uCMS: p=0.0218; CT vs auCMS: p=0.0802; 
Fig 13). Fluoxetine-treated animals could significantly restore the functional circadian regulation 
of the auCMS-exposed animals (F(1,20)=5.409, p=0.0307; auCMS vs auCMS+Flx: p= p=0.0365; Fig 
13). 
 
 
F igure 13. Corticosterone levels measured in the serum of rats between 8:00 and 9:00 am (basal levels; nadir, N) and 
between 8:00 pm and 9:00 pm (peak levels; zenith, Z). This figure shows corticosterone levels of manual -stressed 
animals, automated-stressed animals, non-stressed animals as well as fluoxetine-treated animals. Abbreviations: CT, 
control; uCMS, manual stressed animals; auCMS, automated stressed animals injected with vehicle; auCMS+FlX, 
automated stressed animals treated with fluoxetine. Data is presented as mean ± SEM. *p<0.05; **p<0.01. n= 6-10 
animals per group.  
 
3.3.3 Cellular alterations - proliferation 
Additionally we assessed the proliferation levels in the hippocampal DG. It is known that 
animals exposed to uCMS show a decrease in cellular proliferation in the DG. This phenotype is 
reverted after antidepressants treatment. As such, we evaluated proliferation in auCMS treated 
and non-treated animals(63,64).  
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The number of proliferating cells assessed where dependent of the ones available on the 
tissue collection, since some tissue slices were damaged during the process. 
Using immunofluorescence techniques with BrdU staining (one injection before the 
sacrifice), it was possible to see a significant increase in the number of proliferating cells 
(t(32)=2.505, p=0.0175) of the auCMS-treated group when compared to the auCMS non-treated 
group (Fig 16).  
 
 
F igure 14. Number of proliferating cells in the dorsal dentate gyrus of auCMS-exposed animals untreated and treated 
with fluoxetine. Abbreviations: auCMS, automated stressed animals injected with vehicle; auCMS+FlX, automated 
stressed animals treated with fluoxetine. Data is presented as mean ± SEM. *p<0.05. n=3 animals per group, 3-11 
neurons per animal.  
 
3.3.4 Cellular alterations – Neuronal morphology in the hippocampal DG 
Apart from behaviour analysis other approaches are also relevant to characterize the 
uCMS model. Therefore, brain tissue was obtained after sacrifice and it was analyzed to assess 
cellular alterations. Neurons morphology was assessed in the hippocampal DG, since it is a region 
known to be affected by chronic stress exposure; a shrinkage of the dendrites and a reduction in 
the dendrites complexity is seen as a consequence of uCMS exposure, with both features being 
reverted after ADs treatment(63).  
Data obtained by 3D reconstruction of dorsal DG neurons is presented in Fig 14.  
Surprisingly, no statistically significant differences were observed in the total dendritic 
length of dorsal DG neurons between CT and chronic stress-exposed animals (CT vs uCMS: 
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p=0.9270; (F(2,92)=3.034, p=0.0529). Regarding dorsal DG neurons of the auCMS group, no 
differences were also detected in the dendritic length when compared to control animals with a 
p=0.9794 (F(2,92)=3.034, p=0.0529; Fig 14). 
As expected, fluoxetine-treated animals presented a higher dendritic length of dorsal DG 
neurons when compared to the auCMS group, although not reaching statistical significance 
(t(56)=1.328, p=0.1897; Fig 14).  
 
 
F igure 15. Morphological analysis (total dendritic length) of neurons from the dorsal hippocampal dentate gyrus of 
control non-stressed, manual-stressed, automated-stressed and fluoxetine-treated animals. A representative image of 
neurons from the different groups are shown above the graphs. Abbreviations: CT, control; uCMS, manual stressed 
animals; auCMS, automated stressed animals injected with vehicle; auCMS+FlX, automated stressed animals treated 
with fluoxetine. Data is presented as mean ± SEM. n= 3-10 animals per group. 
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Regarding dendritic arborization, sholl analysis was performed to assess the complexity 
of neurons (Fig 15). Again, no statistically significant differences were found between groups 
(F(2,1564)=1.788, p=0.1676). Additionally, a comparison between auCMS treated animals and 
auCMS non-treated animals showed an increase of the complexity of dendrites of neurons in the 
dorsal DG of auCMS treated animals (Fig 15). However, significant differences were not found 
between the two groups (F(1,951)=2.051, p=0.1524). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
F igure 16. Morphological analysis – Sholl analysis of neurons from the dorsal dentate gyrus of control non-stressed, 
manual-stressed, automated-stressed and fluoxetine-treated animals. Both treated and non-treated groups were 
analyzed. Abbreviations: CT, control; uCMS, manual stressed animals; auCMS, automated stressed animals injected 
with vehicle; auCMS+FlX, automated stressed animals treated with fluoxetine. Data is presented as mean ± SEM. n=3-
5 animals per group, 6-12 neurons per animal. 
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4. DISCUSSION 
An increasing interest in standardizing scientific protocols and tools has been emerging 
among the scientific communities. 
Clinical devices or equipments for human samples processing are upgraded to achieve more 
accurate, rapid and reproducible results (92,93). To a lesser extent, this has also been happening 
for pre-clinical research. Along this discussion I will try to cover some of the attempts made in 
this field to standardize preclinical animal research. 
Researchers have pointed out the importance of both system and biologic validation in 
order to use robotized approaches in the laboratory(94). In line with that, in this validation study, 
we started by individually testing the stressors and then we performed a full validation of the 
uCMS protocol. 
 
4.1 Equipment development and optimization 
Besides the reliability of this chronic stress model seen in independent research groups, the 
biggest limitation of the model is still the lack of reproducibility among sets and laboratories(79). 
Literature regarding the automatization of depression protocols is practically non-existent. Two 
big reasons may be referred as potential causes for this lack of reproducibility - several variability 
sources,  as well as difficulty of processes’  implementation . 
I will start by analysing the main contributors of procedure difficulties(79): 
 
1) Labour- intensity  work and demand of time  
To overcome these, we begun by building a mechanical structure (e.g. open 3 lids at once) 
that reduces the labour-intensity and allows a faster manipulation of the cages for stressors 
implementation and for cleaning activities. This type of easy-manipulation strategies as already 
been described in pre-clinical protocols(95).  
Looking at the protocol itself we identify particular stressors, like tilted-cage (TA) and 
damp bedding (TA) which are very physically demanding and time-consuming. Through our 
modifications, it is possible to remotely control the system and implement the stressors without 
the presence of the experimenter in the animal facility.  Confinement (PA) is another stressor that 
implies much work and time. This stressor can be implemented through different ways, like 
restrain one animal in a cylinder(96,97) or place three animals inside a plastic box with restrained 
space and air(5,59) – the one we used to perform uCMS. As such, we decided to develop a more 
practical alternative that wouldn’t involve the manipulation of the animals, another important 
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point to be discussed ahead. Our proposed method it is not a totally automated stress, although 
it decreases the time per cage from 60s to 5s as well as the work involved.  
 
2) Space constraint  
Since most of the protocols are performed with a big number of animals, the space 
required to perform tilt-cage or confinement may be a constraint for several laboratories. The 
prototype presented here can reduce it to the space of a regular rack since all the cages are 
incorporated in the equipment. 
 
Regarding the variability between laboratories no clear factors have been previously and 
systematically identified. However, some speculations have been made regarding the causative 
factors (77,79,98). Next, I discuss these possible factors more in depth: 
 
1) Divergences between  protocols  
Design variations such as permutations between stressors, time of testing or logistics seem 
to play an important role in the uCMS outcomes. To overcome these issues some protocol 
alterations were implemented, the automation of the tilted-cage stressor (TA) allow us to place 
the animals with the same inclination (previously programmed), at the same time. Also, the 
original damp bedding stress (TA) would often leads to a supply of uneven quantities of water, 
something that does not occur with our auCMS protocol.  
Apart from that, it is still important to ameliorate some issues that could have contributed 
to the divergences.  For instance, the control computer had the lights of the screen on because it 
was placed in the same room as the equipment, this illumination could have interfered with the 
protocol and could have influenced the light-cycle of the animals (it must be corrected in further 
protocols). 
Some opportunities may appear by taking advantage of the equipment features because it 
allows to perform the protocol in an automated equipment it is possible to programme the 
system to introduce stressors in the active period of the animals (at night). This approach could 
be explored in order to better understand the influence of performing stressors in 
diurnal/nocturnal period for the effectiveness of depression-induction protocol, in fact it was 
observed that rats who were stressed during their active period (night) did not display signs of 
depressive and anxiety-related behaviours(98). Another interesting topic that could be assessed 
is the impact of different stressor-permutation levels along active or non-active period may have 
on the effectiveness of depression-induction protocol. 
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2) Differences in housing conditions   
Stressed and control animals are housed in different rooms. An important parameter to 
be monitored in the housing conditions is the ventilation since the circulation of pheromones as 
well as other external odour stimuli may interfere with the animal model induction and with the 
behaviour of control animals(99). These parameters did not suffer any alteration since this 
already happened in our animal facilities.  
It is relevant to say that the automated equipment is not silent (e.g. engine activity for 
tilted cage) and it is not advisable to keep it in a room near the control animals. To solve this 
question a noise isolation box for the engine may be considered in the future. 
Other research groups have been exploring the relevance of the housing conditions for 
the development of depressive-like behaviour, by researching alternative solutions to house the 
animals in a more naturalistic way. Standard housing conditions that increase sensory, cognitive, 
motor and social stimulation are being proposed for rats and mice(95). A particular example is 
PhW - PhenoWorld, a different paradigm that was created to better mimic normal environmental 
conditions(100).  
 
3) Influence from the operator 
Alternative methods to perform behavioural tests in a more fluent and integrated 
manner are being studied. An example of that occurs in PhW paradigm where animals are video-
taped in their home cages in order to measure sleep duration and social interaction without 
disturbing them(100). Another example is the growing use of ultrasonic vocalizations(85,101), a 
methodology where animals are also assessed in their housing environment without the need of 
experimenter manipulation(101), these new methodologies will allow the achievement of more 
realistic conditions.  
Similarly, stress induction protocols may also be influenced by the operator, namely 
regarding different handling experimenters or intensities. Indeed, stressed animals are more 
handled than control ones which may raise behavioural alterations that are impossible to control. 
When compared to the original, our protocol offers a solution to reduce this problem.  For 
example, in our new proposed confinement (PA) we eliminate the need to manipulate the 
animals. 
Another key issue of behavioural tests is the experimenter bias, which is influenced by 
subjective ratings. Indeed, scoring criteria vary within observers despite similar instructions(102). 
In that concern, an increasing number of equipments for rodents’ activity measurement is being 
developed. These devices enable to analyze FST, NOR or social defeat with a faster data 
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acquisition as well as the production of more accurate results as the subjective operator influence 
is not present  (102,103). It is relevant to say that our behavioural tests, particularly FST and NOR, 
where measured using these type of equipments.  
These softwares and devices for the automatic measurement of behaviour phenotyping have 
been patented, highlighting the growing importance and interest on this area(104,105). 
 
4) Animal variances  
Intrinsic inter-animal variances are much difficult to control. Even among the same strain 
it is possible to see differences between suppliers, due to the genetic background or rearing 
procedures. Additionally, the composition of the gut microbiota, which may vary according to the 
housing conditions, has been increasingly seen as an influencing factor for the development of 
depressive and anxiety-like behaviour. Supporting this idea is the common observation of co-
morbidities between GI disorders and MD(106) as well as associations between severity of 
gastrointestinal symptoms and abuse experiences (related to mood disorders)(106,107).  
 
Overall, our prototype is capable of improving the main operating difficulties found in the 
original uCMS protocol as well as several variability sources. These improvements are of particular 
usefulness because uCMS protocol is very long and demanding. 
In sum, with the construction of this equipment we intend to improve uCMS protocol 
effectiveness through a more rigorous and discerning approach, in line to what has been 
published in the literature. In fact, the creation of standardized methods is crucial to clearly 
identify putative sources of variability and achieve reproducibility.  Soon, a patent application will 
be filled as a result of the development of this equipment. 
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4.2 Pilot study phase  
After accomplishing the aim of construction and optimization of the automated 
equipment, we proceeded to a pilot study in order to validate it. In this pilot study (1st protocol 
developed with the equipment) a small cohort of animals was exposed to a six-week uCMS 
protocol. 
In this study we wanted to compare the manual uCMS protocol results with the outcomes 
obtained for the automated uCMS protocol, here described. For that, we showed some 
preliminary results regarding the comparison of both protocols, including behavioural outcomes 
(face validity), treatment efficiency (predictive validity) as well as molecular and cellular findings 
(construct validity). 
Indeed, uCMS protocol has been previously validated as one of the most reliable models 
for depressive-like behaviour induction due to its aetiology validity as well as its completely 
fulfilment of the validation criteria for animal models.(5,70,77) 
Depression is a multi-dimensional disorder that presents high comorbidity with anxiety(6) 
as well as cognitive impairments(7). In fact, several behavioural dimensions (mood, anxiety and 
cognition) are often impaired in depressed patients and animal models of this disease. 
Consequently an extensive behavioural evaluation with a broader perspective must be applied in 
order to get closer to what is seen in clinics(5).  
In this context, several behavioural tests were performed to evaluate the impact of 
chronic stress exposure in the 3 dimensions affected by depression, through the following 
sequence: SPT > SDT > NOR in the 6th week and NSF > FST in the 7th week of the protocol. In the 
6th week of the uCMS protocol the most sensitive tests were performed and in the 7 th week the 
most aggressive ones were performed, to not cause any interference between them. 
The SPT is known as a gold standard-test to measure anhedonic behaviour(79). This test 
is not extremely sensitive and requires relatively big sets of animals to obtain consistent results, 
as some animals do not perform the test. Due to that, we decided to use the SDT as a 
complementary test, since this new approach was developed to assess the same behavioural 
domain as the SPT - anhedonia. Both manual and automated uCMS protocols induced slightly 
lower preference levels for sucrose solution and sweet pellets; however, statistical differences 
were only reached with uCMS manual protocol. According to the literature (77,108) and to 
previous experiments of our team, tests to evaluate anhedonia are challenging and the intra-
group variability may be a concern. As previously referred, in this case, the small number of 
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animals may be an explanation for the lack of statistical differences between controls and auCMS-
exposed animals. 
The FST is a learned helplessness test developed by Porsolt(109), where a passive 
immobility behaviour is measured. This test has a more extreme/aggressive nature, in fact some 
authors use it as a depression model(110). This is also a gold standard test to assess depressive-
like behaviour in rodents but still controversial as some authors argue that immobility is largely 
dependent on learning/memory and may be a result of habituation; also the acute efficacy of 
antidepressant treatment in this test does not mimic clinics (111,112). Here, the FST results 
showed that chronically stressed animals presented increased levels of immobility when 
compared to control ones. Interestingly, the auCMS-exposed animals, in particular, showed a 
worse performance, statistically significant from the non-stressed animals which was already 
reported in PhW (a new ethological enriched paradigm that tries to reduce manipulation 
influence) where uCMS rats from the PhW demonstrated increased levels of behaviour despair 
compared to the ones in standard conditions(113). 
Cognitive function, specifically long term and short term memory, were assessed through 
NOR - a behavioural test based on object-recognition task, commonly used to study 
memory(86,87). As expected, our results show a reduced discrimination index of LTM and STM 
for both stress protocols when compared to controls. Interestingly, statistical significance was 
only achieved between control and auCMS group. 
Anxiety levels were measured by NSF, where higher latency to feeding in the open field 
was used as an index of an increased anxiety-like behaviour. Previous studies report the increased 
levels of anxiety in uCMS animals, which was statistically confirmed in our results for both 
protocols (manual and automated)(5,59). Interestingly, auCMS showed a “stronger” phenotype 
since differences between CT vs auCMS were more evident than CT vs uCMS.  
Despite the lack of statistical differences between auCMS vs CT for SDT and SPT, all the 
other tests show severe results between auCMS vs CT than uCMS vs CT. As stated before 
difficulties in performing these two behavioural tests may be an explanation, however it would 
be interesting to complete this analysis with USVs, known to be related with anhedonic 
behaviour.  
Altogether our results suggest that all the 3 behavioural dimensions are impaired in 
animals subjected to the automated exposure to chronic stress, similarly to what is observed with 
the manual chronic stress-exposure protocol(5). Although these results must be confirmed in 
another set of animals, face validity of the auCMS protocol can be considered fulfilled. 
Fluoxetine administration was used to assess predictive validity. This antidepressant is 
widely used in the clinics and belongs to the Selective Serotonin Re-uptake Inhibitors (SSRIs). 
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Fluoxetine was chosen because it is known to improve depressive symptoms in humans and also 
reverses depressive-like behaviour signs in animal models of depression. Importantly, previous 
studies have shown the ability of fluoxetine to revert depressive-like behaviour in animals 
exposed to uCMS(5,85). Similarly, our results show a slightly better performance in the 
behavioural tests of treated animals when compared to non-treated, suggesting a predictive 
validity of the automated protocol. Again, the lack of statistical significant results may be due to 
the low number of animals used in this pilot study. Thus, these results should be confirmed  in the 
future with a larger set of animals. 
Corticosterone measurement are usually a molecular assay used to verify the efficacy of 
stress exposure protocols(85,114) since chronic stress leads to a disruption of the normal 
circadian corticosterone production(90). The circadian rhythm of corticosterone in control 
animals is usually characterized by low levels in the morning and a peak at the beginning of the 
night phase (animals’ active phase)(91). The HPA-axis is one of the systems responsible for 
controlling GRs release; after chronic stress exposure animals display an hyperactivity of this 
system which leads to a deregulation of the GC secretion-pattern into the blood (90,115). Here, 
we observed an alteration of the circadian regulation of corticosterone secretion in chronic 
stressed animals and a reversion of the corticosterone levels to normal patterns after treatment 
with fluoxetine. These results confirm the successful stress induction of the animals using the 
automated protocol (as it is observed in the manual protocol) and a reestablishment of the 
normal circadian rhythm after antidepressant treatment of auCMS group. 
Concerning cellular alterations, neurons morphology in the dorsal hippocampal DG was 
evaluated using Golgi-staining.  
Previous studies of uCMS-triggered depressive-like behaviour showed alterations in the 
neuronal morphology in the hippocampal DG. Dendritic atrophy of dorsal neurons was seen 
through the reduction of dendritic length; also a decrease of ramifications number and alterations 
in dendritic distribution was reported through 3D sholl analysis (morphological characterization 
of neurons based on concentric circles positioned at radial intervals of 20 µm)(47,48,66). Our 
results failed to show changes in the dendritic length and in the complexity of dorsal DG neurons 
of animals exposed to both protocols of chronic stress. As the number of animals used for these 
analyses was very small, at the moment the results are inconclusive for both stressed groups and 
so, it is not possible to take further conclusions. Fluoxetine treatment increased the length and 
complexity of neurons from animals of auCMS protocol, although not reaching statistical 
significance. Our results are thus in line with the literature since a reversion of the induced 
morphological changes was observed in neuromorphological studies in the hippocampus and 
PFC(63,82). Similarly, other ADs, like TCA and MAOIs were shown to restore dendritic plasticity 
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and thus it is expected that they would also be able to reverse the effects of auCMS(63,64) – an 
interesting experiment that could be included to enrich this work.  
In the future, it will be important to analyze other regions known to be affected in 
depression, like the prefrontal cortex. Deficits in executive function characterize stress-related 
disorders(5) and post mortem analysis of depressed patients show morphological changes in 
neurons and glial cells of PFC. Also, preclinical studies show that chronic stress impair functional 
synaptic plasticity (LTP reduction) in the hippocampal-PFC connections(33,97). Taking that in 
mind, PFC is a frequently explored region in depression models and it will be relevant to address 
in this context in the future. Additionally, we expect also to analyze other parameters related to 
dendritic and synaptic plasticity such as spine numbers and spine morphology, since it was 
reported that chronic stress reduce spine density in hippocampus and PFC. (22,59,63). These 
approaches will help us to better characterize and validate the cellular/plastic alterations induced 
by chronic stress exposure in our proposed method.  
Previous work had shown that uCMS protocol have an impact on cellular proliferation; 
stressed animals are known to present reduced levels of proliferation, neurogenesis and 
gliogenesis in the dorsal DG of the hippocampus (45,52). In fact, long-lasting, sustained remission 
of the impaired dimensions of depression is dependent of neurogenesis(59,66). Due to time 
constraints, our results only assessed whether there was a difference between fluoxetine-treated 
animals exposed to auCMS and the ones exposed to stress that were not treated. As expected, 
we observed an increase in the number of cells being generated in the dorsal hippocampal DG 
after fluoxetine treatment, which is consistent with the literature(59,64). Indeed, animals 
exposed to uCMS protocol display impaired neurogenesis with reversion after AD 
treatment(59,64). Although the analysis of the neuronal morphology in the DG was not 
conclusive, molecular results suggest a validation of the construct criteria. As such, construct 
validity was only partially fulfilled in this pilot study of the auCMS protocol. 
 In this study, we did not analyze cell fate, in further experiments it will be useful to add 
another marker to identify cells fate (e.g. doublecortin (DCX) for immature neurons), this 
suggestion could help to specify and detail our results.  Another suggestion is to analyze 
gliogenesis which has been more recently correlated with the pathophysiology of depression 
(63,117).  
Together, our results suggest that the auCMS protocol implemented has partially fulfilled 
construct validity, face and predicted validity. 
According to Belzung, another parameter which is important to discuss is the right choice 
of the animal for the model, according to biological features(68). In fact, the strain of rats used in 
this work (Wistar Han rats) has been consistently described as an appropriate strain to study 
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depression. Additionally, responses to behavioural tests using this strain have been validated for 
all the dimensions affected by depression(5,77,82). Also, our laboratory has been using and 
validating this strain for several years and so, an internal validity is established (with 
reproducibility and inter-observer reliability). These findings, lead us to consider that the 
homological criteria was fulfilled.  
In summary, our results suggest that, the automated protocol of chronic stress exposure 
can mimic to a large extent the manual protocol. Moreover, the automated protocol lead to more 
evident deficits in anxiety and depressive-like behaviour, as well as to memory impairments. The 
reduced influence of the operator manipulation as well as the application of slightly more intense 
stressors when using the automated rack are most likely playing an important role. 
 
4.3 Main limitations 
To conclude some limitations were identified. During the 6th week protocol some 
electrotechnical failures were detected and corrected. In the future it would be important to have 
a video-camera in order to monitor the protocol during 24h to assess the problems, as soon as 
possible. Another limitation of this work is the reduced number of animals used, in fact this small 
number was chosen due to the preliminary nature of the work.  
The equipment being tested has other features beyond the ones that were tested. This work 
was mainly restricted to the uCMS protocol however, as it was explained before, it is also possible 
to perform a CUS protocol since it is capable of incorporating stressors from this protocol.  
 
The development of this equipment is a crucial innovation for Bn’ML, since it will allow 
them to be positioned as the first company to try to standardize the depression induction 
protocol through the development of an automated equipment for rats. Due to that, services for 
pharmaceutical companies may be provided with more accuracy. 
Beyond that, this innovation is fundamental for the improvement of the actual pre-
clinical research approaches. Pharmaceutical companies will be able to test their drugs in a more 
standardized way, which is a step forward to the global implementation of this model and a 
powerful contributor to a better screen of novel drugs. 
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